generic_name,reasoning,less_determination,binary_determination,less_determination_score,binary_determination_score,issue_with_summaries,
VALGANCICLOVIR HYDROCHLORIDE,"The drug label for Valganciclovir for oral solution mentions dermatological and cutaneous risks and reactions in the following sections:
 

 1. **Adverse Reactions in Adults:**
  - **Skin and subcutaneous tissues disorders:** The label lists ""dermatitis"" and ""pruritus"" (itching) as adverse reactions. 
  - **Summary:** Valganciclovir itself is associated with dermatitis and pruritus.
 

 2. **Other Adverse Reactions in Clinical Trials:**
  - **Skin and subcutaneous tissues disorders:** The label mentions ""dermatitis"" and ""night sweats"" as reactions observed in clinical trials.
  - **Summary:** Valganciclovir itself is associated with dermatitis and night sweats.
 

 3. **Other Adverse Reactions in Clinical Trials (less than 5% of patients):**
  - **Skin and subcutaneous tissues disorders:** The label lists ""dermatitis"" and ""pruritus"" as reactions occurring in less than 5% of patients.
  - **Summary:** Valganciclovir itself is associated with dermatitis and pruritus in less than 5% of patients.
 

 4. **Patient Information:**
  - **Common Side Effects in Adults:** The label lists ""rash"" as a common side effect.
  - **Summary:** Valganciclovir itself is associated with causing rash in adults.
 

 5. **Patient Information:**
  - **Common Side Effects in Children:** The label lists ""rash"" as a common side effect.
  - **Summary:** Valganciclovir itself is associated with causing rash in children.
 

 In summary, Valganciclovir for oral solution is associated with several dermatological and cutaneous reactions, including dermatitis, pruritus, night sweats, and rash in both adults and children.",Less,Yes,1,1,,
PENTOXIFYLLINE,"### Summary of Dermatological and Cutaneous Risks and Reactions for Pentoxifylline Extended-Release Tablets
 

 1. **Skin and Appendages (Adverse Reactions Section)**
  - **Reported Symptoms**: Brittle fingernails, pruritus (itching), rash, urticaria (hives), angioedema (swelling similar to hives but under the skin).
  - **Association with Drug**: These symptoms have been reported spontaneously since marketing or occurred in other clinical trials with an incidence of less than 1%. The causal relationship to pentoxifylline is uncertain.
 

 2. **Special Senses (Adverse Reactions Section)**
  - **Reported Symptoms**: Blurred vision, conjunctivitis (inflammation of the eye), earache, scotoma (partial loss of vision or a blind spot).
  - **Association with Drug**: These symptoms have been reported spontaneously since marketing or occurred in other clinical trials with an incidence of less than 1%. The causal relationship to pentoxifylline is uncertain.
 

 3. **Miscellaneous (Adverse Reactions Section)**
  - **Reported Symptoms**: Bad taste, excessive salivation, leukopenia (reduction in white blood cells), malaise, sore throat/swollen neck glands, weight change.
  - **Association with Drug**: These symptoms have been reported spontaneously since marketing or occurred in other clinical trials with an incidence of less than 1%. The causal relationship to pentoxifylline is uncertain.
 

 4. **Rare Events (Adverse Reactions Section)**
  - **Reported Symptoms**: Angina, arrhythmia, tachycardia, hepatitis, jaundice, cholestasis, increased liver enzymes, decreased serum fibrinogen, pancytopenia, aplastic anemia, leukemia, purpura, thrombocytopenia, anaphylactic reaction, anaphylactoid reaction, anaphylactic shock.
  - **Association with Drug**: These rare events have been reported spontaneously worldwide since marketing in 1972. Although they occurred under circumstances in which a causal relationship with pentoxifylline could not be established, they are listed to serve as information for physicians.
 

 ### Conclusion
 The drug label for pentoxifylline extended-release tablets mentions several dermatological and cutaneous symptoms, including brittle fingernails, pruritus, rash, urticaria, and angioedema. However, the causal relationship between these symptoms and the drug is uncertain. Additionally, some rare events have been reported, but a direct causal link to pentoxifylline has not been established.",Less,Yes,1,1,,
ERTAPENEM SODIUM,"### Summary of Dermatological and Cutaneous Risks and Reactions for INVANZ
 

 1. **Warnings and Precautions (Section 5.1)**
  - **Hypersensitivity Reactions**: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams, including INVANZ. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens. (INVANZ is associated with this risk.)
 

 2. **Adverse Reactions (Section 6.1)**
  - **Adults**: The most common adverse reactions (≥5%) in patients treated with INVANZ were diarrhea, nausea, headache, and infused vein complication. (No specific dermatological reactions mentioned here.)
  - **Pediatrics**: Adverse reactions in this population were comparable to adults. The most common adverse reactions (≥5%) in pediatric patients treated with INVANZ were diarrhea, vomiting, and infusion site pain. (No specific dermatological reactions mentioned here.)
 

 3. **Clinical Trials Experience (Section 6.1)**
  - **Adults Receiving INVANZ as a Treatment Regimen**: Additional adverse experiences reported with INVANZ with an incidence >0.1% within each body system include:
  - **Skin & Skin Appendage**: Erythema, sweating, dermatitis, desquamation, flushing, urticaria. (INVANZ is associated with these reactions.)
  - **Prophylaxis of Surgical Site Infection following Elective Colorectal Surgery**: Additional adverse experiences reported in this prophylaxis trial with INVANZ, regardless of causality, with an incidence >0.5% within each body system include:
  - **Skin and Subcutaneous Tissue Disorders**: Dermatitis, pruritus, rash erythematous, skin lesion. (INVANZ is associated with these reactions.)
  - **Pediatric Patients Receiving INVANZ as a Treatment Regimen**: Additional adverse experiences reported with INVANZ with an incidence >0.5% within each body system include:
  - **Skin and Subcutaneous Tissue Disorders**: Dermatitis, pruritus, rash erythematous, skin lesion. (INVANZ is associated with these reactions.)
 

 4. **Post-Marketing Experience (Section 6.2)**
  - **Skin and Subcutaneous Tissue Disorders**: Acute Generalized Exanthematous Pustulosis (AGEP), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome), hypersensitivity vasculitis. (INVANZ is associated with these reactions.)
 

 ### Summary
 - **INVANZ is associated with several dermatological and cutaneous risks and reactions**, including erythema, sweating, dermatitis, desquamation, flushing, urticaria, pruritus, rash erythematous, skin lesions, Acute Generalized Exanthematous Pustulosis (AGEP), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome), and hypersensitivity vasculitis.
 - These reactions have been reported in both clinical trials and post-marketing experiences.
 - Serious hypersensitivity reactions, including anaphylactic reactions, have also been reported and are more likely in individuals with a history of sensitivity to multiple allergens.",Most,Yes,1,1,,
SEVELAMER CARBONATE,"The drug label for Renvela (sevelamer carbonate) mentions dermatological and cutaneous risks and reactions in the following sections:
 

 1. **Section 6.2 Postmarketing Experience**:
  - ""The following adverse reactions have been identified during postapproval use of sevelamer hydrochloride or sevelamer carbonate: hypersensitivity, pruritus, rash...""
  - **Summary**: The drug (sevelamer hydrochloride or sevelamer carbonate) has been associated with hypersensitivity, pruritus (itching), and rash.
 

 2. **Section 7 Drug Interactions**:
  - ""During postmarketing experience, cases of increased thyroid stimulating hormone (TSH) levels have been reported in patients coadministered sevelamer hydrochloride and levothyroxine.""
  - **Summary**: This sentence does not directly discuss dermatological risks or reactions.
 

 3. **Section 8.2 Lactation**:
  - ""Sevelamer carbonate may decrease serum levels of fat-soluble vitamins and folic acid in pregnant women.""
  - **Summary**: This sentence does not directly discuss dermatological risks or reactions.
 

 4. **Section 8.4 Pediatric Use**:
  - ""Most adverse events that were reported as related, or possibly related, to sevelamer carbonate were gastrointestinal in nature.""
  - **Summary**: This sentence does not directly discuss dermatological risks or reactions.
 

 In summary, the drug label indicates that sevelamer carbonate (Renvela) has been associated with dermatological reactions such as hypersensitivity, pruritus, and rash.",Less,Yes,1,1,,
DESVENLAFAXINE ER,"Here is a summary of all the parts of the drug label that discuss dermatological and cutaneous risks and dermatological reactions for Desvenlafaxine ER:
 

 1. **Hypersensitivity**:
  - **Sentence**: ""Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the desvenlafaxine formulation.""
  - **Summary**: The drug itself is associated with hypersensitivity reactions.
 

 2. **Adverse Reactions**:
  - **Sentence**: ""Rash, alopecia, photosensitivity reaction, angioedema.""
  - **Summary**: The drug itself is associated with rash, hair loss (alopecia), sensitivity to light (photosensitivity reaction), and swelling (angioedema).
 

 3. **Postmarketing Experience**:
  - **Sentence**: ""Skin and subcutaneous tissue disorders - Stevens-Johnson syndrome.""
  - **Summary**: The drug itself has been associated with Stevens-Johnson syndrome, a severe skin reaction.
 

 4. **Warnings and Precautions**:
  - **Sentence**: ""Advise patients to notify their physician if they develop allergic phenomena such as rash, hives, swelling, or difficulty breathing.""
  - **Summary**: The drug itself may cause allergic reactions including rash and hives.
 

 5. **Medication Guide**:
  - **Sentence**: ""Allergic Reactions: Advise patients to notify their physician if they develop allergic phenomena such as rash, hives, swelling, or difficulty breathing.""
  - **Summary**: The drug itself may cause allergic reactions including rash and hives.
 

 In summary, Desvenlafaxine ER is associated with several dermatological and cutaneous risks, including rash, alopecia, photosensitivity reaction, angioedema, and Stevens-Johnson syndrome. Patients are advised to notify their physician if they develop any allergic reactions such as rash or hives.",Most,Yes,1,1,,
LISDEXAMFETAMINE,"Here is a summary of the parts of the drug label that discuss dermatological and cutaneous risks and reactions for lisdexamfetamine dimesylate:
 

 1. **Contraindications (Section 4)**
  - **Known hypersensitivity to amphetamine products or other ingredients of lisdexamfetamine dimesylate capsules.** 
  - **Summary:** The drug is associated with hypersensitivity reactions, including dermatological reactions such as anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria.
 

 2. **Warnings and Precautions (Section 5.6)**
  - **Peripheral Vasculopathy, including Raynaud’s Phenomenon:**
  - **Summary:** The drug is associated with peripheral vasculopathy, including Raynaud’s phenomenon, which can cause digital changes such as numbness, pain, and color changes in fingers or toes.
 

 3. **Adverse Reactions (Section 6.1)**
  - **In the controlled trial in pediatric patients ages 6 to 12 years, the most frequently reported adverse reactions included rash.**
  - **Summary:** The drug caused rash in pediatric patients.
  - **In the controlled trial in pediatric patients ages 13 to 17 years, less frequently reported adverse reactions included dermatillomania.**
  - **Summary:** The drug was associated with dermatillomania in pediatric patients.
  - **In the controlled adult trial, less frequently reported adverse reactions included rash.**
  - **Summary:** The drug caused rash in adult patients.
 

 4. **Postmarketing Experience (Section 6.2)**
  - **The following adverse reactions have been identified during post-approval use of lisdexamfetamine dimesylate: Stevens-Johnson Syndrome, chest pain, angioedema, urticaria, and alopecia.**
  - **Summary:** The drug is associated with Stevens-Johnson Syndrome, angioedema, urticaria, and alopecia.
 

 5. **Patient Counseling Information (Section 17)**
  - **Circulation Problems in Fingers and Toes [Peripheral Vasculopathy, Including Raynaud’s Phenomenon]:**
  - **Summary:** The drug is associated with peripheral vasculopathy, including Raynaud’s phenomenon, which can cause dermatological symptoms such as numbness, pain, and color changes in fingers or toes.
 

 In summary, lisdexamfetamine dimesylate is associated with several dermatological and cutaneous risks and reactions, including hypersensitivity reactions (such as Stevens-Johnson Syndrome, angioedema, and urticaria), peripheral vasculopathy (including Raynaud’s phenomenon), rash, dermatillomania, and alopecia.",Most,Yes,1,1,,
MIDAZOLAM,"The drug label for Midazolam in Sodium Chloride Injection mentions dermatological and cutaneous risks and reactions in the following sections:
 

 1. **Warnings and Precautions (5.7) - Risk of Intra-Arterial Injection**:
  - ""There have been limited reports of intra-arterial injection of midazolam. Adverse events have included local reactions, as well as isolated reports of seizure activity in which no clear causal relationship was established.""
  - **Summary**: The drug itself was associated with local reactions when administered intra-arterially.
 

 2. **Adverse Reactions (6) - Other Adverse Reactions Occurring at an Incidence of <1.0% Following Intravenous Injection as a Single Sedative/Anxiolytic/Amnesia Agent**:
  - **Integumentary**:
  - ""Hive-like elevation at injection site, swelling or feeling of burning, warmth or coldness at injection site.""
  - **Summary**: The drug itself was associated with hive-like elevation, swelling, and sensations of burning, warmth, or coldness at the injection site.
  - **Hypersensitivity**:
  - ""Allergic reactions including anaphylactic reactions, hives, rash, pruritus.""
  - **Summary**: The drug itself was associated with allergic reactions, including hives, rash, and pruritus (itching).
 

 These sections indicate that Midazolam in Sodium Chloride Injection can cause or is associated with various dermatological and cutaneous reactions, particularly at the site of injection and as part of hypersensitivity reactions.",Less,Yes,1,1,,
ZIPRASIDONE MESYLATE,"### Summary of Dermatological and Cutaneous Risks and Reactions for GEODON (Ziprasidone)
 

 1. **Severe Cutaneous Adverse Reactions (Section 5.5)**
  - **Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS):** 
  - **Association:** DRESS has been reported with ziprasidone exposure.
  - **Details:** DRESS includes a combination of cutaneous reactions (such as rash or exfoliative dermatitis), eosinophilia, fever, lymphadenopathy, and systemic complications like hepatitis, nephritis, pneumonitis, myocarditis, and pericarditis. DRESS is sometimes fatal.
  - **Action:** Discontinue ziprasidone if DRESS is suspected.
  - **Other Severe Cutaneous Adverse Reactions:**
  - **Association:** Severe cutaneous adverse reactions, such as Stevens-Johnson syndrome, have been reported with ziprasidone exposure.
  - **Details:** These reactions are sometimes fatal.
  - **Action:** Discontinue ziprasidone if severe cutaneous adverse reactions are suspected.
 

 2. **Rash (Section 5.8)**
  - **Association:** In premarketing trials, about 5% of patients developed rash and/or urticaria with ziprasidone.
  - **Details:** The occurrence of rash was related to the dose of ziprasidone. Several patients with rash had signs and symptoms of associated systemic illness, such as elevated white blood cells (WBCs). Most patients improved with adjunctive treatment or upon discontinuation of ziprasidone.
  - **Action:** Discontinue ziprasidone upon the appearance of rash for which an alternative etiology cannot be identified.
 

 3. **Adverse Reactions in Clinical Trials (Section 6.1)**
  - **Schizophrenia Trials:**
  - **Association:** Rash was reported in 4% of ziprasidone-treated patients compared to 3% of placebo-treated patients.
  - **Bipolar Disorder Trials:**
  - **Association:** Rash was one of the most common reactions associated with dropout in ziprasidone-treated patients (1%) compared to placebo patients (1%).
  - **Intramuscular Ziprasidone Trials:**
  - **Association:** Furunculosis (a type of skin infection) was reported in 2% of patients receiving 10 mg of intramuscular ziprasidone.
 

 4. **Postmarketing Experience (Section 6.2)**
  - **Association:** Allergic reactions such as allergic dermatitis, angioedema, orofacial edema, urticaria, and rash have been reported with ziprasidone.
 

 5. **Patient Counseling Information (Section 17)**
  - **Severe Cutaneous Adverse Reactions:**
  - **Association:** Instruct patients to report any signs or symptoms that may be associated with DRESS or severe cutaneous adverse reactions, such as Stevens-Johnson syndrome, to their healthcare provider.
 

 ### Conclusion
 GEODON (ziprasidone) has been associated with several dermatological and cutaneous risks, including severe cutaneous adverse reactions like DRESS and Stevens-Johnson syndrome, as well as more common reactions such as rash and urticaria. These reactions can be serious and sometimes fatal, necessitating discontinuation of the drug if they occur. Patients should be advised to report any signs of these reactions to their healthcare provider immediately.",Most,Yes,1,1,,
XYLOCAINE (LIDOCAINE HCL ),"Here is a summary of the parts of the drug label that discuss dermatological and cutaneous risks and reactions for Xylocaine (lidocaine HCl):
 

 1. **Warnings Section:**
  - **Sodium Metabisulfite Sensitivity:** ""Xylocaine with epinephrine solutions contain sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people."" 
  - **Summary:** Sodium metabisulfite in the drug may cause allergic-type reactions, including dermatological reactions, in susceptible individuals.
 

 2. **Adverse Reactions Section:**
  - **Allergic Reactions:** ""Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions.""
  - **Summary:** The drug itself may cause allergic reactions, including cutaneous lesions and urticaria (hives).
  - **Allergic Reactions Management:** ""Allergic reactions may occur as a result of sensitivity either to local anesthetic agents or to the methylparaben used as a preservative in the multiple dose vials.""
  - **Summary:** The drug or its preservative methylparaben may cause allergic reactions, including dermatological reactions.
  - **Allergic Reactions Frequency:** ""Allergic reactions, including anaphylactic reactions, may occur as a result of sensitivity to lidocaine, but are infrequent.""
  - **Summary:** The drug itself may infrequently cause allergic reactions, including dermatological reactions.
 

 3. **Sterilization, Storage, and Technical Procedures Section:**
  - **Disinfecting Agents:** ""Disinfecting agents containing heavy metals, which cause release of respective ions (mercury, zinc, copper, etc) should not be used for skin or mucous membrane disinfection as they have been related to incidents of swelling and edema.""
  - **Summary:** Disinfecting agents containing heavy metals, not the drug itself, are associated with dermatological risks such as swelling and edema.
 

 In summary, the drug label indicates that Xylocaine (lidocaine HCl) and its components (such as sodium metabisulfite and methylparaben) may cause dermatological reactions like cutaneous lesions, urticaria, and edema. Additionally, the use of certain disinfecting agents with the drug can lead to dermatological risks, although these are not caused by the drug itself.",Less,Yes,1,1,,
ECALLANTIDE,"### Summary of Dermatological and Cutaneous Risks and Reactions for KALBITOR (ecallantide)
 

 1. **Warnings and Precautions (Section 5.1)**
  - **Hypersensitivity Reactions, Including Anaphylaxis**: 
  - **Symptoms**: The drug itself was associated with symptoms such as pruritus (itching), urticaria (hives), and rash. These symptoms are indicative of hypersensitivity reactions, including anaphylaxis, which have occurred in patients treated with KALBITOR.
 

 2. **Adverse Reactions (Section 6)**
  - **Clinical Trials Experience (Section 6.1)**:
  - **Injection Site Reactions**: The drug itself caused injection site reactions in 7% of patients. These reactions were characterized by local pruritus (itching), erythema (redness), pain, irritation, urticaria (hives), and/or bruising.
  - **Other Adverse Reactions**: The drug itself was associated with pruritus (itching) in 5% of patients and rash in 3% of patients.
 

 3. **Medication Guide (Section 17)**
  - **Possible Side Effects**:
  - **Common Side Effects**: The drug itself caused injection site reactions, such as redness, rash, swelling, itching, or bruising.
 

 ### Conclusion
 KALBITOR (ecallantide) is associated with several dermatological and cutaneous risks and reactions, including pruritus, urticaria, rash, and various injection site reactions such as redness, swelling, and bruising. These reactions are indicative of hypersensitivity and are relatively common among patients treated with the drug.",Most,Yes,1,1,,
HYDROCODONE BITARTRATE,"The drug label for HYSINGLA® ER (hydrocodone bitartrate) mentions several dermatological and cutaneous risks and reactions. Here is a summary of those parts:
 

 1. **Warnings and Precautions (Section 5.13)**
  - **Gastrointestinal Obstruction, Dysphagia, and Choking**: In the clinical studies, 11 out of 2476 subjects reported difficulty swallowing HYSINGLA ER, which included esophageal obstruction, dysphagia, and choking. This indicates that the drug itself was associated with these reactions.
 

 2. **Adverse Reactions (Section 6.1)**
  - **Most Common Adverse Reactions**: The most common treatment-emergent adverse events (incidence ≥ 5%) include pruritus (itching). This indicates that the drug itself was associated with causing pruritus.
  - **Common Adverse Reactions (≥1% to <5%)**: The common adverse reactions reported by patients treated with HYSINGLA ER in the chronic pain clinical trials include rash and hyperhidrosis (excessive sweating). This indicates that the drug itself was associated with causing rash and hyperhidrosis.
  - **Less Common Adverse Reactions (<1%)**: Other less common adverse reactions include flushing. This indicates that the drug itself was associated with causing flushing.
 

 3. **Postmarketing Experience (Section 6.2)**
  - **Hyperalgesia and Allodynia**: Cases of hyperalgesia (increased sensitivity to pain) and allodynia (pain from ordinarily non-painful stimuli) have been reported with opioid therapy of any duration. This indicates that the drug itself was associated with causing hyperalgesia and allodynia.
 

 In summary, HYSINGLA ER has been associated with several dermatological and cutaneous reactions, including pruritus, rash, hyperhidrosis, flushing, hyperalgesia, and allodynia. These reactions were either observed in clinical trials or reported postmarketing, indicating a direct association with the drug.",Less,Yes,1,1,,
DIAZEPAM INTENSOL,"The drug label for Diazepam Intensol™ Oral Solution mentions dermatological and cutaneous risks and reactions in the following sections:
 

 1. **Adverse Reactions - Skin and Appendages**:
  - **Sentence**: ""Skin reactions""
  - **Summary**: The drug itself is associated with causing skin reactions.
 

 2. **Adverse Reactions - Postmarketing Experience**:
  - **Sentence**: ""There have been reports of falls and fractures in benzodiazepine users. The risk is increased in those taking concomitant sedatives (including alcohol), and in the elderly.""
  - **Summary**: This sentence does not directly discuss dermatological risks but mentions falls and fractures, which are not dermatological reactions.
 

 3. **Drug Abuse and Dependence - Abuse**:
  - **Sentence**: ""The following adverse reactions have occurred with benzodiazepine abuse and/or misuse: ... formication...""
  - **Summary**: The drug itself, when abused or misused, is associated with causing formication, a sensation that resembles insects crawling on or under the skin.
 

 In summary, the drug label indicates that Diazepam Intensol™ Oral Solution is associated with causing skin reactions and formication when abused or misused.",Less,Yes,1,1,,
EPLONTERSEN,"The drug label for WAINUA (eplontersen) includes the following information related to dermatological and cutaneous risks and reactions:
 

 1. **Injection Site Reactions**:
  - **Sentence**: ""Injection site reactions includes erythema, pain, and pruritis.""
  - **Summary**: The drug WAINUA is associated with injection site reactions, which include erythema (redness), pain, and pruritis (itching).
 

 2. **Adverse Reactions in Clinical Trials**:
  - **Sentence**: ""Table 1: Adverse Reactions Reported in at least 5% of Patients Treated with WAINUA (Study 1)... Injection site reactions includes erythema, pain, and pruritis.""
  - **Summary**: In clinical trials, WAINUA was associated with injection site reactions, including erythema, pain, and pruritis, occurring in at least 5% of patients.
 

 3. **General Adverse Reactions**:
  - **Sentence**: ""The most common adverse reactions of WAINUA include decreased vitamin A and vomiting.""
  - **Summary**: While not directly dermatological, decreased vitamin A can potentially lead to skin issues, though the label does not specify this directly.
 

 4. **Patient Information**:
  - **Sentence**: ""WAINUA is injected under your skin (subcutaneously) in your stomach area (abdomen), or the front of your upper legs (thighs) by you or a caregiver. A caregiver may also give you an injection of WAINUA in the outer area of your upper arm.""
  - **Summary**: The drug WAINUA is administered subcutaneously, which inherently involves the skin and can lead to injection site reactions.
 

 5. **Instructions for Use**:
  - **Sentence**: ""Do not inject within 2 inches (5 cm) of the belly button (navel); into skin that is bruised, tender, red, or hard; into scars or damaged skin.""
  - **Summary**: The drug WAINUA should not be injected into areas of the skin that are bruised, tender, red, hard, scarred, or otherwise damaged, indicating a precaution to avoid exacerbating existing skin conditions.
 

 In summary, WAINUA is associated with dermatological risks primarily related to injection site reactions, including erythema, pain, and pruritis. The drug label advises against injecting into compromised skin areas to prevent further skin issues.",Less,Yes,1,1,,
SODIUM ACETATE,"The provided drug label for Sodium Acetate Injection, USP (2 mEq/mL) does not specifically mention any dermatological or cutaneous risks or reactions. The label primarily focuses on the drug's usage, administration, contraindications, warnings, precautions, and potential adverse reactions related to sodium and acetate ions, but it does not address any skin-related issues.
 

 To summarize:
 - **No dermatological risks or reactions are mentioned**: The drug label does not associate Sodium Acetate Injection, USP with any dermatological or cutaneous risks or reactions.",No,No,1,1,,
PRALSETINIB,"The drug label for GAVRETO (pralsetinib) includes several mentions of dermatological and cutaneous risks and reactions. Here is a summary of those parts:
 

 1. **Adverse Reactions (6.1 Clinical Trials Experience)**
  - **Rash**: The drug label states that rash, including dermatitis acneiform, eczema, palmar-plantar erythrodysaesthesia syndrome, rash erythematous, rash macular, rash maculo-papular, rash papular, and rash pustular, occurred in 17% of patients with non-small cell lung cancer (NSCLC) who received GAVRETO. This indicates that the drug itself was associated with causing these dermatological reactions.
 

 2. **RET-altered Thyroid Cancer (Table 7: Adverse Reactions)**
  - **Rash**: The drug label mentions that rash, including dermatitis, dermatitis acneiform, eczema, palmar-plantar erythrodysaesthesia syndrome, rash erythematous, rash macular, rash maculo-papular, rash papular, and rash pustular, occurred in 24% of patients with RET-altered thyroid cancer who received GAVRETO. This indicates that the drug itself was associated with causing these dermatological reactions.
 

 3. **Patient Information (17 PATIENT COUNSELING INFORMATION)**
  - **Risk of Impaired Wound Healing**: The drug label advises that GAVRETO may impair wound healing. This indicates that the drug itself is associated with a risk of impaired wound healing.
 

 4. **Patient Information Leaflet**
  - **Risk of Wound Healing Problems**: The leaflet advises that wounds may not heal properly during treatment with GAVRETO and that patients should inform their healthcare provider if they plan to have any surgery. This indicates that the drug itself is associated with a risk of impaired wound healing.
 

 In summary, GAVRETO is associated with causing various dermatological reactions such as rash and dermatitis, and it also poses a risk of impaired wound healing.",Most,Yes,1,1,,
SUMATRIPTAN SUCCINATE U-D,"The drug label for Sumatriptan tablets includes several sections that discuss dermatological and cutaneous risks and reactions. Here is a summary of those parts:
 

 1. **Warnings and Precautions (5.9 Anaphylactic/Anaphylactoid Reactions)**:
  - **Summary**: Anaphylactic/anaphylactoid reactions have occurred in patients receiving sumatriptan.
  - **Association**: The drug itself was associated with these reactions.
 

 2. **Adverse Reactions (6.2 Postmarketing Experience)**:
  - **Summary**: The postmarketing experience includes reports of hypersensitivity reactions, including anaphylaxis and angioedema.
  - **Association**: The drug itself was associated with these reactions.
 

 3. **Patient Information**:
  - **Summary**: Patients are advised to be aware of hives (itchy bumps) and swelling of the tongue, mouth, or throat as potential side effects.
  - **Association**: The drug itself was associated with these reactions.
 

 In summary, the drug label indicates that Sumatriptan tablets are associated with dermatological risks such as anaphylactic/anaphylactoid reactions, hypersensitivity reactions including anaphylaxis and angioedema, and hives.",Most,Yes,2,1,,"*i think less may be more appropriate here clinically, but if going based off of the summary, mention of anaphylactic shock would make it most and therefore a 1"
DIHYDROERGOTAMINE,"### Summary of Dermatological and Cutaneous Risks and Reactions
 

 1. **Local Irritation**:
  - **Summary**: Approximately 30% of patients using dihydroergotamine mesylate nasal spray reported irritation in the nose, throat, and/or disturbances in taste. Symptoms included congestion, burning sensation, dryness, paraesthesia, discharge, epistaxis, pain, or soreness.
  - **Association**: The drug itself was associated with these irritative symptoms.
 

 2. **Skin and Appendages**:
  - **Frequent Adverse Events**:
  - **Summary**: Infrequent adverse events included petechia, pruritus, rash, and cold clammy skin.
  - **Association**: The drug itself was associated with these skin-related adverse events.
  - **Rare Adverse Events**:
  - **Summary**: Rare adverse events included papular rash, urticaria, and herpes simplex.
  - **Association**: The drug itself was associated with these rare skin-related adverse events.
 

 3. **Application Site**:
  - **Summary**: Infrequent adverse events included local anesthesia.
  - **Association**: The drug itself was associated with this application site reaction.
 

 ### Detailed Breakdown
 

 1. **Local Irritation**:
  - **Details**: The symptoms were predominantly mild to moderate in severity and transient. In approximately 70% of cases, the symptoms resolved within four hours after dosing with dihydroergotamine mesylate nasal spray.
  - **Association**: The drug itself was associated with these symptoms.
 

 2. **Skin and Appendages**:
  - **Infrequent Adverse Events**:
  - **Details**: Petechia, pruritus, rash, and cold clammy skin were reported infrequently.
  - **Association**: The drug itself was associated with these infrequent adverse events.
  - **Rare Adverse Events**:
  - **Details**: Papular rash, urticaria, and herpes simplex were reported rarely.
  - **Association**: The drug itself was associated with these rare adverse events.
 

 3. **Application Site**:
  - **Details**: Local anesthesia was reported infrequently.
  - **Association**: The drug itself was associated with this application site reaction.
 

 ### Conclusion
 Dihydroergotamine mesylate nasal spray is associated with several dermatological and cutaneous risks, including local irritation, infrequent skin reactions like petechia and pruritus, and rare reactions such as papular rash and urticaria. These reactions are directly linked to the use of the drug.",Less,Yes,1,1,,
REPOSITORY CORTICOTROPIN,"### Summary of Dermatological and Cutaneous Risks and Reactions for Purified Cortrophin Gel
 

 1. **Indications and Usage:**
  - **Dermatologic diseases:** The drug is indicated for severe erythema multiforme (Stevens-Johnson syndrome) and severe psoriasis. 
  - **Association:** The drug is used to treat these conditions, not cause them.
 

 2. **Warnings:**
  - **Masking Symptoms of Other Diseases:** Corticotropin may only suppress symptoms and signs of chronic disease without altering the natural course of the disease.
  - **Association:** The drug may mask dermatological symptoms but does not cause them.
 

 3. **Adverse Reactions:**
  - **Dermatologic:**
  - **Injection site reactions:** The drug can cause reactions at the site of injection.
  - **Association:** The drug itself causes this reaction.
  - **Impaired wound healing:** The drug can impair the healing of wounds.
  - **Association:** The drug itself causes this reaction.
  - **Increased sweating:** The drug can cause increased sweating.
  - **Association:** The drug itself causes this reaction.
  - **Thin fragile skin:** The drug can cause the skin to become thin and fragile.
  - **Association:** The drug itself causes this reaction.
  - **Suppression of skin test reactions:** The drug can suppress reactions to skin tests.
  - **Association:** The drug itself causes this reaction.
  - **Petechiae and ecchymoses:** The drug can cause small red or purple spots (petechiae) and larger bruises (ecchymoses) on the skin.
  - **Association:** The drug itself causes this reaction.
  - **Acne:** The drug can cause acne.
  - **Association:** The drug itself causes this reaction.
  - **Hyperpigmentation:** The drug can cause darkening of the skin.
  - **Association:** The drug itself causes this reaction.
  - **Facial erythema:** The drug can cause redness of the face.
  - **Association:** The drug itself causes this reaction.
 

 4. **Precautions:**
  - **General:** Skin testing should be performed prior to treatment of all patients with suspected sensitivity to porcine protein. Immediately following intramuscular or subcutaneous administration of corticotropin, all patients should be observed carefully for sensitivity reactions.
  - **Association:** The drug may cause sensitivity reactions, including dermatological ones.
 

 ### Conclusion
 Purified Cortrophin Gel is associated with several dermatological and cutaneous risks and reactions, including injection site reactions, impaired wound healing, increased sweating, thin fragile skin, suppression of skin test reactions, petechiae and ecchymoses, acne, hyperpigmentation, and facial erythema. These reactions are directly caused by the drug. Additionally, the drug is used to treat severe dermatological conditions like erythema multiforme and psoriasis, but it does not cause these conditions.",Most,Yes,1,1,,
MICONAZOLE NITRATE,"### Summary of Dermatological and Cutaneous Risks and Reactions for Miconazole Nitrate Vaginal Suppositories
 

 1. **General Precautions:**
  - **Discontinue drug if sensitization or irritation is reported during use.**
  - **Summary:** The drug itself can cause sensitization or irritation, and its use should be discontinued if these reactions occur.
 

 2. **Adverse Reactions:**
  - **The incidence of vulvovaginal burning, itching, or irritation was 2%.**
  - **Summary:** The drug itself was associated with vulvovaginal burning, itching, or irritation in 2% of patients.
  - **Complaints of cramping (2%) and headaches (1.3%) were also reported. Other complaints (hives, skin rash) occurred with less than a 0.5% incidence.**
  - **Summary:** The drug itself was associated with hives and skin rash in less than 0.5% of patients.
 

 3. **Patient Instructions:**
  - **If your partner has any penile itching, redness, or discomfort, he should consult his physician and mention that you are being treated for a yeast infection.**
  - **Summary:** The drug itself may indirectly cause penile itching, redness, or discomfort in the patient's partner, suggesting a possible dermatological reaction.
 

 ### Conclusion
 The drug label indicates that Miconazole Nitrate Vaginal Suppositories can cause dermatological reactions such as sensitization, irritation, vulvovaginal burning, itching, hives, and skin rash. Additionally, it may indirectly cause penile itching, redness, or discomfort in the patient's partner.",Less,Yes,1,1,,
IVERMECTIN,"### Summary of Dermatological and Cutaneous Risks and Reactions for STROMECTOL (Ivermectin)
 

 1. **General Warnings:**
  - **Mazzotti Reaction:** Historical data indicate that microfilaricidal drugs, including ivermectin, might cause cutaneous reactions of varying severity in patients with onchocerciasis. These reactions are likely due to allergic and inflammatory responses to the death of microfilariae. **(Associated with the drug)**
 

 2. **Adverse Reactions in Strongyloidiasis:**
  - **Pruritus:** Reported in 2.8% of patients. **(Associated with the drug)**
  - **Rash:** Reported in 0.9% of patients. **(Associated with the drug)**
  - **Urticaria:** Reported in 0.9% of patients. **(Associated with the drug)**
 

 3. **Adverse Reactions in Onchocerciasis:**
  - **Mazzotti Reactions:** Worsening of skin involvement, including edema, papular and pustular or frank urticarial rash, was reported in 22.7% of patients during the first 4 days post-treatment. **(Associated with the drug)**
  - **Pruritus:** Reported in 27.5% of patients. **(Associated with the drug)**
  - **Facial Edema:** Reported in 1.2% of patients. **(Associated with the drug)**
  - **Peripheral Edema:** Reported in 3.2% of patients. **(Associated with the drug)**
 

 4. **Post-Marketing Experience:**
  - **Toxic Epidermal Necrolysis:** Reported since the drug was registered overseas. **(Associated with the drug)**
  - **Stevens-Johnson Syndrome:** Reported since the drug was registered overseas. **(Associated with the drug)**
 

 ### Conclusion
 STROMECTOL (Ivermectin) is associated with several dermatological and cutaneous risks and reactions, including pruritus, rash, urticaria, facial and peripheral edema, and severe conditions like toxic epidermal necrolysis and Stevens-Johnson syndrome. These reactions are primarily linked to the drug itself and its effects on the death of microfilariae in patients with onchocerciasis.",Most,Yes,1,1,,
ERIBULIN MESYLATE,"The provided drug label for Halaven® (eribulin mesylate) injection does not contain any specific information or sentences discussing dermatological and cutaneous risks or dermatological reactions. The label primarily includes details about the drug's composition, storage instructions, manufacturing information, and general usage for intravenous administration. 
 

 Therefore, based on the provided text, there are no mentions of dermatological risks or reactions associated with the drug Halaven® (eribulin mesylate).",No,No,1,1,,
GEMTUZUMAB OZOGAMICIN,"The drug label for MYLOTARG (gemtuzumab ozogamicin) includes several mentions of dermatological and cutaneous risks and reactions. Here is a summary of those parts:
 

 1. **Infusion-Related Reactions (Including Anaphylaxis)**:
  - **Sentence**: ""Signs and symptoms of infusion-related reactions may include fever, chills, hypotension, tachycardia, hypoxia and respiratory failure.""
  - **Summary**: The drug itself is associated with infusion-related reactions, which can include dermatological symptoms such as rash.
 

 2. **Adverse Reactions**:
  - **Sentence**: ""The most common adverse reactions (greater than 15%) were hemorrhage, infection, fever, nausea, vomiting, constipation, headache, increased AST, increased ALT, rash, mucositis, febrile neutropenia, and decreased appetite.""
  - **Summary**: The drug itself is associated with common adverse reactions, including rash.
 

 3. **Clinical Trials Experience**:
  - **Sentence**: ""During the treatment period, Grade 3 treatment-emergent adverse events (TEAEs) that occurred in greater than 1% patients included sepsis (32%), fever (16%), rash (11%), pneumonia (7%), bleeding (7%), mucositis (4%), pain (4%), diarrhea (2%), headaches (2%), tachycardia (2%), and lung edema (2%).""
  - **Summary**: The drug itself is associated with Grade 3 treatment-emergent adverse events, including rash.
 

  - **Sentence**: ""All grade TEAEs that occurred in greater than 15% of patients included fever (79%), infection (42%), increased AST (40%), bleeding (23%), nausea and vomiting (21%), constipation (21%), mucositis (21%), headache (19%), increased ALT (16%), and rash (16%).""
  - **Summary**: The drug itself is associated with all-grade treatment-emergent adverse events, including rash.
 

 4. **Postmarketing Experience**:
  - **Sentence**: ""The following adverse drug reactions have been identified during post-approval use of MYLOTARG. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.""
  - **Summary**: The drug itself is associated with adverse drug reactions identified during post-approval use, including dermatological reactions such as rash.
 

 In summary, MYLOTARG is associated with dermatological risks and reactions, including rash, as part of its infusion-related reactions, common adverse reactions, treatment-emergent adverse events, and postmarketing experience.",Most,Yes,1,1,,
FELBAMATE,"### Summary of Dermatological and Cutaneous Risks and Reactions for Felbatol® (felbamate)
 

 1. **Warnings Section:**
  - **Suicidal Behavior and Ideation:** This section does not specifically mention dermatological risks but highlights the importance of monitoring for unusual changes in mood or behavior, which could indirectly relate to dermatological reactions due to stress or anxiety.
 

 2. **Adverse Reactions Section:**
  - **Common Adverse Reactions in Adults (Monotherapy):**
  - **Acne:** Felbatol® was associated with acne in 3.4% of patients.
  - **Rash:** Felbatol® was associated with rash in 3.4% of patients.
  - **Common Adverse Reactions in Adults (Adjunctive Therapy):**
  - **Rash:** Felbatol® was associated with rash in 3.5% of patients.
  - **Common Adverse Reactions in Children (Adjunctive Therapy):**
  - **Rash:** Felbatol® was associated with rash in 9.7% of pediatric patients.
  - **Other Events Observed in Association with Felbatol®:**
  - **Frequent:** Pruritus (itching) was frequently associated with Felbatol®.
  - **Infrequent:** Urticaria (hives) and bullous eruption (blistering) were infrequently associated with Felbatol®.
  - **Rare:** Buccal mucous membrane swelling and Stevens-Johnson Syndrome (a severe skin reaction) were rarely associated with Felbatol®.
 

 3. **Postmarketing Adverse Event Reports:**
  - **Voluntary Reports:**
  - **Dermatological:** Abnormal body odor, sweating, lichen planus (a chronic skin condition), livedo reticularis (a skin condition characterized by a mottled discoloration), alopecia (hair loss), and toxic epidermal necrolysis (a severe skin reaction) were reported. These reports are voluntary and may not have a direct causal relationship with Felbatol®.
 

 ### Summary of Each Sentence:
 1. **Acne (Monotherapy):** Felbatol® was associated with acne in 3.4% of patients.
 2. **Rash (Monotherapy):** Felbatol® was associated with rash in 3.4% of patients.
 3. **Rash (Adjunctive Therapy in Adults):** Felbatol® was associated with rash in 3.5% of patients.
 4. **Rash (Adjunctive Therapy in Children):** Felbatol® was associated with rash in 9.7% of pediatric patients.
 5. **Pruritus:** Felbatol® was frequently associated with pruritus.
 6. **Urticaria:** Felbatol® was infrequently associated with urticaria.
 7. **Bullous Eruption:** Felbatol® was infrequently associated with bullous eruption.
 8. **Buccal Mucous Membrane Swelling:** Felbatol® was rarely associated with buccal mucous membrane swelling.
 9. **Stevens-Johnson Syndrome:** Felbatol® was rarely associated with Stevens-Johnson Syndrome.
 10. **Abnormal Body Odor:** Voluntary reports associated Felbatol® with abnormal body odor.
 11. **Sweating:** Voluntary reports associated Felbatol® with sweating.
 12. **Lichen Planus:** Voluntary reports associated Felbatol® with lichen planus.
 13. **Livedo Reticularis:** Voluntary reports associated Felbatol® with livedo reticularis.
 14. **Alopecia:** Voluntary reports associated Felbatol® with alopecia.
 15. **Toxic Epidermal Necrolysis:** Voluntary reports associated Felbatol® with toxic epidermal necrolysis.
 

 ### Conclusion:
 Felbatol® (felbamate) has been associated with various dermatological and cutaneous reactions, including acne, rash, pruritus, urticaria, bullous eruption, buccal mucous membrane swelling, and Stevens-Johnson Syndrome. Additionally, postmarketing reports have linked it to abnormal body odor, sweating, lichen planus, livedo reticularis, alopecia, and toxic epidermal necrolysis, although these reports may not establish a direct causal relationship.",Most,Yes,1,1,,
DICLOFENAC POTASSIUM,"### Summary of Dermatological and Cutaneous Risks and Reactions for CAMBIA (Diclofenac Potassium)
 

 1. **Serious Skin Reactions**:
  - **Sentence**: ""NSAIDs, including diclofenac, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal.""
  - **Summary**: CAMBIA (diclofenac) is associated with causing serious skin reactions, including exfoliative dermatitis, SJS, and TEN, which can be fatal.
 

 2. **Discontinuation at First Appearance of Skin Rash**:
  - **Sentence**: ""Inform patients about the signs and symptoms of serious skin reactions, and to discontinue the use of CAMBIA at the first appearance of skin rash or any other sign of hypersensitivity.""
  - **Summary**: Patients should discontinue CAMBIA if they experience a skin rash or other signs of hypersensitivity, indicating that the drug can cause these reactions.
 

 3. **Contraindication in Patients with Previous Serious Skin Reactions**:
  - **Sentence**: ""CAMBIA is contraindicated in patients with previous serious skin reactions to NSAIDs.""
  - **Summary**: CAMBIA should not be used in patients who have had serious skin reactions to NSAIDs, suggesting that the drug itself can cause such reactions.
 

 4. **Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)**:
  - **Sentence**: ""Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as CAMBIA.""
  - **Summary**: CAMBIA is associated with causing DRESS, a serious and potentially life-threatening condition.
 

 5. **Signs and Symptoms of DRESS**:
  - **Sentence**: ""DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling.""
  - **Summary**: CAMBIA can cause DRESS, which may present with symptoms including rash.
 

 6. **Early Manifestations of Hypersensitivity**:
  - **Sentence**: ""It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.""
  - **Summary**: CAMBIA can cause early hypersensitivity reactions, which may include rash.
 

 7. **Serious Skin Reactions in Postmarketing Experience**:
  - **Sentence**: ""In patients taking diclofenac or other NSAIDs, the most frequently reported adverse reactions occurring in approximately 1%-10% of patients are: rashes.""
  - **Summary**: CAMBIA has been associated with causing rashes in 1%-10% of patients.
 

 8. **Life-threatening Skin Reactions**:
  - **Sentence**: ""CAMBIA, like other NSAIDS, can cause serious skin reactions such as exfoliative dermatitis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and DRESS, which may result in hospitalizations and even death.""
  - **Summary**: CAMBIA can cause life-threatening skin reactions, including exfoliative dermatitis, SJS, TEN, and DRESS.
 

 9. **Patient Counseling Information**:
  - **Sentence**: ""Advise patients to stop taking CAMBIA immediately if they develop any type of rash, blisters, fever or other signs of hypersensitivity such as itching and to contact their healthcare provider as soon as possible.""
  - **Summary**: Patients should stop taking CAMBIA if they develop a rash, blisters, or other signs of hypersensitivity, indicating that the drug can cause these reactions.
 

 10. **Medication Guide**:
  - **Sentence**: ""CAMBIA can cause serious side effects, including: life-threatening skin reactions.""
  - **Summary**: CAMBIA is associated with causing life-threatening skin reactions.
 

 11. **Medication Guide - Emergency Help**:
  - **Sentence**: ""Get emergency help right away if you get any of the following symptoms: skin rash or blisters with fever.""
  - **Summary**: CAMBIA can cause skin rash or blisters with fever, requiring emergency help.
 

 12. **Medication Guide - Stop Taking CAMBIA**:
  - **Sentence**: ""Stop taking CAMBIA and call your healthcare provider right away if you get any of the following symptoms: skin rash or blisters with fever.""
  - **Summary**: Patients should stop taking CAMBIA if they develop a skin rash or blisters with fever, indicating that the drug can cause these reactions.
 

 ### Conclusion
 CAMBIA (diclofenac potassium) is associated with several serious dermatological and cutaneous risks, including life-threatening conditions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Patients are advised to discontinue use and seek medical attention if they experience any signs of skin reactions or hypersensitivity.",Most,Yes,1,1,,
LEFLUNOMIDE,"### Summary of Dermatological and Cutaneous Risks and Reactions for ARAVA (leflunomide)
 

 1. **Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, and Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS)**
  - **Summary**: Rare cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS have been reported in patients receiving ARAVA.
  - **Association**: The drug itself was associated with these severe dermatological reactions.
 

 2. **Warnings and Precautions (Section 5.5)**
  - **Summary**: If a patient taking ARAVA develops Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS, ARAVA treatment should be stopped, and an accelerated drug elimination procedure should be performed.
  - **Association**: The drug itself was associated with these conditions, necessitating discontinuation and elimination procedures.
 

 3. **Adverse Reactions (Section 6.1)**
  - **Summary**: The most commonly reported adverse reactions (≥10%) regardless of relation to ARAVA treatment included rash.
  - **Association**: The drug itself was associated with rash as a common adverse reaction.
 

 4. **Less Common Adverse Reactions (Section 6.1)**
  - **Summary**: In controlled clinical trials, the following adverse events in the ARAVA treatment group occurred at a higher incidence than in the placebo group and were deemed possibly related to the study drug: rash, alopecia, and pruritus.
  - **Association**: The drug itself was associated with rash, alopecia, and pruritus as less common adverse reactions.
 

 5. **Postmarketing Experience (Section 6.2)**
  - **Summary**: The following additional adverse reactions have been identified during postapproval use of ARAVA: erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, vasculitis including cutaneous necrotizing vasculitis, cutaneous lupus erythematosus, pustular psoriasis, or worsening psoriasis, and skin ulcer.
  - **Association**: The drug itself was associated with these severe dermatological reactions based on postmarketing reports.
 

 6. **Patient Counseling Information (Section 17)**
  - **Summary**: Advise patients of the possibility of rare, serious skin reactions and instruct them to promptly report if they develop a skin rash or mucous membrane lesions.
  - **Association**: The drug itself was associated with the potential for serious skin reactions, warranting patient education and prompt reporting.
 

 ### Conclusion
 ARAVA (leflunomide) is associated with several dermatological and cutaneous risks, including severe conditions like Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, erythema multiforme, vasculitis, cutaneous lupus erythematosus, pustular psoriasis, and skin ulcers. Common adverse reactions include rash, alopecia, and pruritus. Patients should be advised to report any skin reactions promptly.",Most,Yes,1,1,,
SODIUM FLUORIDE F-18,"The drug label for Sodium Fluoride F 18 Injection does not mention any dermatological or cutaneous risks or reactions. Specifically:
 

 1. **Adverse Reactions Section (6)**: 
  - The label states, ""No adverse reactions have been reported for Sodium Fluoride F 18 Injection based on a review of the published literature, publicly available reference sources, and adverse drug reaction reporting systems."" This indicates that no dermatological or cutaneous reactions have been associated with or caused by the drug.
 

 Therefore, based on the provided drug label, there are no reported dermatological or cutaneous risks or reactions associated with Sodium Fluoride F 18 Injection.",No,No,1,1,,
MICAFUNGIN,"### Summary of Dermatological and Cutaneous Risks and Reactions for Micafungin for Injection
 

 1. **Warnings and Precautions: Infusion and Injection Site Reactions**
  - **Possible histamine-mediated symptoms**: The drug itself was associated with rash, pruritus, facial swelling, and vasodilatation. (Section 5.5)
 

 2. **Adverse Reactions: Clinical Trials Experience in Adults**
  - **Esophageal Candidiasis Study**: The drug itself was associated with rash in 14% of patients treated with micafungin for injection compared to 10% in the fluconazole group. (Table 4, Section 6.1)
  - **Prophylaxis of Candida Infections in Hematopoietic Stem Cell Transplant Recipients**: The drug itself was associated with rash in 25% of patients treated with micafungin for injection compared to 22% in the fluconazole group. (Table 5, Section 6.1)
 

 3. **Adverse Reactions: Clinical Trials Experience in Pediatric Patients**
  - **Prophylaxis Study in Pediatric Patients**: The drug itself was associated with pruritus in 33% of patients treated with micafungin for injection compared to 31% in the fluconazole group. Rash was reported in 30% of patients treated with micafungin for injection compared to 27% in the fluconazole group. Urticaria was reported in 19% of patients treated with micafungin for injection compared to 8% in the fluconazole group. (Table 6, Section 6.1)
 

 4. **Postmarketing Experience**
  - **Skin and subcutaneous tissue disorders**: The drug itself was associated with Stevens-Johnson syndrome and toxic epidermal necrolysis. (Section 6.2)
 

 5. **Nonclinical Toxicology**
  - **Animal Toxicology and/or Pharmacology**: High doses of the drug itself have been associated with irreversible changes to the liver, which may be indicative of pre-malignant processes, but no specific dermatological risks were mentioned in this section. (Section 13.2)
 

 ### Conclusion
 Micafungin for Injection has been associated with several dermatological and cutaneous risks and reactions, including rash, pruritus, facial swelling, vasodilatation, Stevens-Johnson syndrome, and toxic epidermal necrolysis. These reactions were observed in both adult and pediatric clinical trials, as well as in postmarketing reports.",Most,Yes,1,1,,
CEFOTAXIME,"Here is a summary of the parts of the drug label that discuss dermatological and cutaneous risks and reactions for Cefotaxime for Injection, USP:
 

 1. **Warnings Section:**
  - **Hypersensitivity Reactions:** The drug label warns that serious hypersensitivity reactions, including dermatological reactions, may occur with cefotaxime. This indicates that the drug itself is associated with these risks.
 

 2. **Adverse Reactions Section:**
  - **Cutaneous Reactions:** The label mentions that isolated cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme have been reported with cefotaxime. This indicates that the drug itself has been associated with these severe dermatological reactions.
  - **Acute Generalized Exanthematous Pustulosis (AGEP):** The label also reports cases of AGEP associated with cefotaxime. This indicates that the drug itself is associated with this specific dermatological reaction.
 

 3. **Clinical Trials Experience:**
  - **Hypersensitivity (2.4%):** The label states that rash and pruritus (itching) have been observed in clinical trials. This indicates that the drug itself caused these dermatological reactions.
 

 4. **Post-Marketing Experience:**
  - **General Disorders and Administration Site Conditions:** The label mentions inflammatory reactions at the injection site, including phlebitis/thrombophlebitis. While this is a local reaction, it is related to the administration of the drug itself.
 

 In summary, the drug label for Cefotaxime for Injection, USP, indicates that the drug itself is associated with various dermatological and cutaneous risks and reactions, including serious hypersensitivity reactions, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, AGEP, rash, pruritus, and inflammatory reactions at the injection site.",Most,Yes,1,1,,
METFORMIN HYDROCHLORIDE EXTENDED-RELEASE,"The drug label for Metformin Hydrochloride Extended-Release Tablets does not explicitly discuss dermatological and cutaneous risks or reactions in detail. However, here is a summary of the relevant sections that might indirectly relate to dermatological concerns:
 

 1. **Adverse Reactions (6.2 Postmarketing Experience)**:
  - ""Cholestatic, hepatocellular, and mixed hepatocellular liver injury have been reported with postmarketing use of metformin.""
  - **Summary**: This sentence does not directly mention dermatological reactions but indicates liver injuries, which can sometimes manifest in skin symptoms such as jaundice. The drug itself was associated with these liver injuries.
 

 2. **Patient Information (17 Patient Counseling Information)**:
  - ""Stop taking metformin hydrochloride extended-release tablets and call your doctor right away if you get any of the following symptoms of lactic acidosis: feel very weak and tired, have unusual (not normal) muscle pain, have trouble breathing, have unexplained stomach or intestinal problems with nausea and vomiting, or diarrhea, have unusual sleepiness or sleep longer than usual, feel cold, especially in your arms and legs, feel dizzy or lightheaded, have a slow or irregular heartbeat.""
  - **Summary**: This sentence lists symptoms of lactic acidosis but does not mention any dermatological reactions. The drug itself is associated with lactic acidosis, which can have systemic effects but is not directly linked to cutaneous symptoms in this context.
 

 3. **Patient Information (What are the possible side effects of metformin hydrochloride extended-release tablets?)**:
  - ""Low blood sugar (hypoglycemia). Low blood sugar is a serious, but common, side effect of metformin hydrochloride extended-release tablets. If you take metformin hydrochloride extended-release tablets with another medicine that can cause low blood sugar, such as sulfonylureas or insulin, you have a higher risk of getting low blood sugar. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take metformin hydrochloride extended-release tablets. Signs and symptoms of low blood sugar may include: headache, drowsiness, weakness, irritability, hunger, fast heartbeat, confusion, shaking or feeling jittery, dizziness, sweating.""
  - **Summary**: This sentence mentions sweating as a symptom of hypoglycemia, which can be a dermatological reaction. The drug itself, when combined with other medications, can cause hypoglycemia, which in turn can lead to sweating.
 

 Overall, the drug label does not provide specific details on dermatological and cutaneous risks or reactions directly caused by Metformin Hydrochloride Extended-Release Tablets. The primary focus is on systemic effects and other adverse reactions.",Less,No,1,1,,
MIRVETUXIMAB SORAVTANSINE,"The drug label for ELAHERE (mirvetuximab soravtansine-gynx) does not explicitly mention dermatological and cutaneous risks or reactions in the provided text. The focus of the label is primarily on ocular toxicity, pneumonitis, peripheral neuropathy, and other systemic adverse reactions. Here is a summary of the relevant sections that might indirectly relate to dermatological or cutaneous concerns:
 

 1. **Ocular Disorders (5.1)**:
  - ELAHERE can cause severe ocular adverse reactions, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis. (The drug itself is associated with these ocular risks.)
 

 2. **Pneumonitis (5.2)**:
  - Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ELAHERE. (The drug itself is associated with this pulmonary risk.)
 

 3. **Peripheral Neuropathy (5.3)**:
  - Peripheral neuropathy occurred in 36% of patients with ovarian cancer treated with ELAHERE across clinical trials. (The drug itself is associated with this neurological risk.)
 

 4. **Adverse Reactions (6.1)**:
  - The most common (≥20%) adverse reactions, including lab abnormalities, were increased aspartate aminotransferase, fatigue, increased alanine aminotransferase, blurred vision, nausea, increased alkaline phosphatase, diarrhea, abdominal pain, keratopathy, peripheral neuropathy, musculoskeletal pain, decreased lymphocytes, decreased platelets, decreased magnesium, decreased hemoglobin, dry eye, constipation, decreased leukocytes, vomiting, decreased albumin, decreased appetite, and decreased neutrophils. (The drug itself is associated with these systemic adverse reactions.)
 

 5. **Clinical Trials Experience (6.1)**:
  - In the pooled safety population, the most common (≥20%) adverse reactions included increased aspartate aminotransferase, fatigue, increased alanine aminotransferase, blurred vision, nausea, increased alkaline phosphatase, diarrhea, abdominal pain, keratopathy, peripheral neuropathy, musculoskeletal pain, decreased lymphocytes, decreased platelets, decreased magnesium, decreased hemoglobin, dry eye, constipation, decreased leukocytes, vomiting, decreased albumin, decreased appetite, and decreased neutrophils. (The drug itself is associated with these systemic adverse reactions.)
 

 6. **Immunogenicity: Anti-Drug Antibody-Associated Adverse Reactions (6.1)**:
  - Infusion reactions (including bronchospasm, erythema, eyelid erythema, flushing, hypersensitivity, periorbital edema, rash, allergic rhinitis, face edema) occurred in 26% of patients with anti-drug antibodies and in 7% who did not develop anti-drug antibodies. (The drug itself is associated with these infusion-related reactions, which include dermatological reactions like erythema and rash.)
 

 In summary, while the drug label for ELAHERE does not specifically highlight dermatological and cutaneous risks as a primary concern, it does mention infusion-related reactions that include erythema and rash. These reactions are associated with the drug, particularly in patients who develop anti-drug antibodies.",Less,Yes,1,1,,
ROSUVASTATIN,"The drug label for EZALLOR SPRINKLE (rosuvastatin) mentions dermatological and cutaneous risks and reactions in the following sections:
 

 1. **Section 6.1 Clinical Trials Experience**:
  - ""Other adverse reactions reported in clinical studies were abdominal pain, dizziness, hypersensitivity (including rash, pruritus, urticaria, and angioedema), and pancreatitis.""
  - **Summary**: The drug itself was associated with hypersensitivity reactions, including rash, pruritus (itching), urticaria (hives), and angioedema (swelling).
 

 2. **Section 6.2 Postmarketing Experience**:
  - ""Skin and Subcutaneous Tissue Disorders: drug reaction with eosinophilia and systemic symptoms (DRESS), lichenoid drug eruption.""
  - **Summary**: The drug itself was associated with drug reaction with eosinophilia and systemic symptoms (DRESS) and lichenoid drug eruption.
 

 3. **Section 17 Patient Counseling Information**:
  - ""Advise patients that EZALLOR SPRINKLE may cause myopathy and rhabdomyolysis. Inform patients that the risk is also increased when taking certain types of medication and they should discuss all medication, both prescription and over the counter, with their healthcare provider. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever.""
  - **Summary**: This section does not directly discuss dermatological risks but focuses on myopathy and rhabdomyolysis, which are not dermatological conditions.
 

 In summary, the drug label indicates that EZALLOR SPRINKLE (rosuvastatin) is associated with dermatological risks such as rash, pruritus, urticaria, angioedema, drug reaction with eosinophilia and systemic symptoms (DRESS), and lichenoid drug eruption.",Most,Yes,2,1,,"*biggest risk is angioedema, may not be considered derm or cutaneous "
DABRAFENIB,"### Summary of Dermatological and Cutaneous Risks and Reactions for TAFINLAR
 

 1. **New Primary Malignancies, Cutaneous and Non-Cutaneous:**
  - **TAFINLAR Monotherapy (Adult):** 
  - **Cutaneous squamous cell carcinomas (cuSCC):** Occurred in 11% of patients. (Associated with TAFINLAR)
  - **Keratoacanthomas:** Occurred in 4% of patients. (Associated with TAFINLAR)
  - **Basal cell carcinoma:** Occurred in 4% of patients. (Associated with TAFINLAR)
  - **New primary melanoma:** Occurred in 1% of patients. (Associated with TAFINLAR)
  - **TAFINLAR Administered with Trametinib (Adult):**
  - **cuSCC (including keratoacanthomas):** Occurred in 2% of patients. (Associated with TAFINLAR and trametinib)
  - **Basal cell carcinoma:** Occurred in 3% of patients. (Associated with TAFINLAR and trametinib)
  - **New primary melanoma:** Occurred in <1% of patients. (Associated with TAFINLAR and trametinib)
  - **TAFINLAR Administered with Trametinib (Pediatric):**
  - **New primary melanoma:** Occurred in <1% of patients. (Associated with TAFINLAR and trametinib)
  - **Monitoring:** Dermatologic evaluations are recommended prior to initiation, every 2 months during therapy, and for up to 6 months following discontinuation of TAFINLAR. (Associated with TAFINLAR)
 

 2. **Serious Skin Toxicities:**
  - **Severe cutaneous adverse reactions (SCARs):** Including Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-threatening or fatal, have been reported during treatment with TAFINLAR administered with trametinib. (Associated with TAFINLAR and trametinib)
  - **TAFINLAR Administered with Trametinib (Adult):**
  - **Other serious skin toxicity:** Occurred in <1% of patients. (Associated with TAFINLAR and trametinib)
  - **TAFINLAR Administered with Trametinib (Pediatric):**
  - **Serious adverse events of skin and subcutaneous tissue disorders:** Occurred in 1.8% of patients. (Associated with TAFINLAR and trametinib)
  - **Monitoring and Management:** Monitor for new or worsening serious skin reactions. Permanently discontinue TAFINLAR for SCARs. For other skin toxicities, withhold TAFINLAR for intolerable or severe skin toxicity. Resume TAFINLAR at a lower dose in patients with improvement or recovery from skin toxicity within 3 weeks. Permanently discontinue TAFINLAR if skin toxicity has not improved within 3 weeks. (Associated with TAFINLAR)
 

 3. **Adverse Reactions in Clinical Trials:**
  - **TAFINLAR as a Single Agent:**
  - **Hyperkeratosis:** Occurred in 37% of patients. (Associated with TAFINLAR)
  - **Alopecia:** Occurred in 22% of patients. (Associated with TAFINLAR)
  - **Palmar-plantar erythrodysesthesia syndrome (PPES):** Occurred in 20% of patients. (Associated with TAFINLAR)
  - **Rash:** Occurred in 17% of patients. (Associated with TAFINLAR)
  - **Papilloma:** Occurred in 27% of patients. (Associated with TAFINLAR)
  - **cuSCC:** Occurred in 7% of patients. (Associated with TAFINLAR)
  - **Photosensitivity:** Observed in less than 10% of patients. (Associated with TAFINLAR)
  - **TAFINLAR with Trametinib:**
  - **Rash:** Occurred in 32% of patients. (Associated with TAFINLAR and trametinib)
  - **Dry skin:** Occurred in 10% of patients. (Associated with TAFINLAR and trametinib)
  - **Panniculitis:** Observed in less than 10% of patients. (Associated with TAFINLAR and trametinib)
  - **Photosensitivity:** Observed in less than 10% of patients. (Associated with TAFINLAR and trametinib)
  - **Adjuvant Treatment of Melanoma:**
  - **Rash:** Occurred in 37% of patients. (Associated with TAFINLAR and trametinib)
  - **NSCLC:**
  - **Rash:** Occurred in 28% of patients. (Associated with TAFINLAR and trametinib)
  - **Advanced BRAF V600E Mutation-Positive Tumors:**
  - **Rash:** Occurred in 40% of patients. (Associated with TAFINLAR and trametinib)
  - **Pediatric Patients with Solid Tumors:**
  - **Rash:** Occurred in 73% of patients. (Associated with TAFINLAR and trametinib)
  - **Dry skin:** Occurred in 48% of patients. (Associated with TAFINLAR and trametinib)
  - **Dermatitis acneiform:** Occurred in 40% of patients. (Associated with TAFINLAR and trametinib)
  - **Pediatric Patients with LGG:**
  - **Rash:** Occurred in 51% of patients. (Associated with TAFINLAR and trametinib)
  - **Dry skin:** Occurred in 26% of patients. (Associated with TAFINLAR and trametinib)
  - **Dermatitis acneiform:** Occurred in 22% of patients. (Associated with TAFINLAR and trametinib)
 

 4. **Postmarketing Experience:**
  - **SCAR (including DRESS and SJS):** Reported during post-approval use of TAFINLAR in combination with trametinib. (Associated with TAFINLAR and trametinib)
 

 ### Patient Counseling Information
 - **Serious Skin Toxicities:** Advise patients that TAFINLAR can cause serious skin toxicities and to contact their healthcare provider for progressive or intolerable rash. Advise patients to contact their healthcare provider immediately if they develop signs and symptoms of a severe skin reaction. (Associated with TAFINLAR)
 

 ### Medication Guide
 - **Risk of New Cancers:** TAFINLAR, when used alone or with trametinib, may cause skin cancers, including cutaneous squamous cell carcinoma (cuSCC), keratoacanthoma, basal cell carcinoma, or melanoma. (Associated with TAFINLAR and trametinib)
 - **Serious Skin Reactions:** TAFINLAR can cause serious skin reactions, including blisters, peeling of the skin, mouth sores, and high fever or flu-like symptoms. (Associated with TAFINLAR)
 

 This summary highlights the dermatological and cutaneous risks and reactions associated with TAFINLAR, both as a monotherapy and in combination with trametinib.",Most,Yes,1,1,,
DULOXETIN HYDROCHLORIDE,"### Summary of Dermatological and Cutaneous Risks and Reactions for Duloxetine Delayed-Release Capsules
 

 1. **Severe Skin Reactions (Section 5.6)**
  - **Summary**: Duloxetine delayed-release capsules may cause severe skin reactions, including erythema multiforme and Stevens-Johnson Syndrome (SJS). The reporting rate of SJS associated with duloxetine use exceeds the general population background incidence rate for this serious skin reaction.
  - **Association**: The drug itself is associated with causing severe skin reactions.
 

 2. **Discontinuation of Treatment (Section 5.7)**
  - **Summary**: Discontinuation symptoms have been systematically evaluated, and during marketing of other SSRIs and SNRIs, there have been spontaneous reports of adverse events, including skin reactions such as rash.
  - **Association**: The drug itself is associated with causing skin reactions upon discontinuation.
 

 3. **Other Adverse Reactions Observed During the Premarketing and Postmarketing Clinical Trial Evaluation (Section 6.10)**
  - **Summary**: Frequent adverse reactions include pruritus. Infrequent reactions include cold sweat, dermatitis contact, erythema, increased tendency to bruise, night sweats, and photosensitivity reaction. Rare reactions include ecchymosis.
  - **Association**: The drug itself is associated with causing these dermatological reactions.
 

 4. **Postmarketing Spontaneous Reports (Section 6.12)**
  - **Summary**: Adverse reactions reported since market introduction that were temporally related to duloxetine therapy include cutaneous vasculitis (sometimes associated with systemic involvement) and rash.
  - **Association**: The drug itself is associated with causing these dermatological reactions.
 

 5. **Patient Counseling Information (Section 17)**
  - **Summary**: Patients should be cautioned that duloxetine delayed-release capsules may cause serious skin reactions that may require stopping its use. This may need to be treated in a hospital and may be life-threatening. Patients should call their doctor right away or get emergency help if they have skin blisters, peeling rash, sores in the mouth, hives, or any other allergic reactions.
  - **Association**: The drug itself is associated with causing these serious skin reactions.
 

 ### Conclusion
 Duloxetine delayed-release capsules are associated with several dermatological and cutaneous risks and reactions, including severe skin reactions like erythema multiforme and Stevens-Johnson Syndrome, pruritus, dermatitis, erythema, photosensitivity, and rash. These reactions can occur during treatment or upon discontinuation of the drug. Patients are advised to seek immediate medical attention if they experience any severe skin reactions.",Most,Yes,1,1,,
BUPIVACAINE HCL COLLAGEN-MATRIX,"### Summary of Dermatological and Cutaneous Risks and Reactions for XARACOLL
 

 1. **Warnings and Precautions (5.2 Methemoglobinemia)**
  - **Sentence:** ""Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood.""
  - **Summary:** The drug itself is associated with methemoglobinemia, which can cause cyanotic skin discoloration.
 

 2. **Adverse Reactions (6.1 Clinical Trial Experience)**
  - **Sentence:** ""The most common adverse reactions (incidence greater than or equal to 2% and higher than placebo implant) following XARACOLL administration were dysgeusia, headache, scrotal swelling, tremor, pyrexia, vision blurred, and seroma.""
  - **Summary:** The drug itself was associated with scrotal swelling, which is a cutaneous reaction.
  - **Sentence:** ""Common incision site adverse reactions (incidence greater than or equal to 2% and higher in either the XARACOLL or placebo implant groups compared to non-implant comparator treatment groups) were swelling pain, other complication, post-procedural discharge, erythema, dehiscence, and inflammation.""
  - **Summary:** The drug itself was associated with incision site swelling, erythema, and inflammation, which are cutaneous reactions.
 

 3. **Adverse Reactions Reported in Phase 3 Placebo-controlled Trials**
  - **Sentence:** ""The most common adverse reactions (incidence greater than or equal to 2% and higher than placebo implants) following XARACOLL administration were incision site swelling, dysgeusia, headache, tremor, vision blurred, seroma, scrotal swelling, pyrexia, hypoesthesia oral, and post procedural discharge.""
  - **Summary:** The drug itself was associated with incision site swelling and scrotal swelling, which are cutaneous reactions.
 

 4. **Postmarketing Experience (6.2)**
  - **Sentence:** ""Allergic-type reactions have occurred as a result of sensitivity to bupivacaine or to other formulation ingredients. These reactions were characterized by signs such as urticaria, pruritus, erythema, angioneurotic edema (including laryngeal edema), tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and severe hypotension.""
  - **Summary:** The drug itself was associated with allergic-type reactions including urticaria, pruritus, and erythema, which are dermatological reactions.
 

 5. **Patient Counseling Information (17)**
  - **Sentence:** ""Assess if the patient has had allergic-type reactions to amide-type local anesthetics or to other formulation ingredients.""
  - **Summary:** The drug itself may cause allergic-type reactions, which can include dermatological reactions.
 

 ### Conclusion
 XARACOLL is associated with several dermatological and cutaneous risks and reactions, including cyanotic skin discoloration due to methemoglobinemia, incision site swelling, erythema, inflammation, scrotal swelling, and allergic-type reactions such as urticaria and pruritus.",Most,Yes,1,1,,
BOSENTAN,"Here is a summary of the parts of the drug label that discuss dermatological and cutaneous risks and reactions for TRACLEER (bosentan):
 

 1. **Hypersensitivity (Section 4.4)**:
  - **Summary**: TRACLEER is contraindicated in patients who are hypersensitive to bosentan or any component of the product. Observed reactions include Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), anaphylaxis, rash, and angioedema.
  - **Association**: The drug itself is associated with these dermatological reactions.
 

 2. **Warnings and Precautions (Section 5.3)**:
  - **Summary**: Hypersensitivity reactions, including DRESS, anaphylaxis, rash, and angioedema, have been reported.
  - **Association**: The drug itself is associated with these dermatological reactions.
 

 3. **Adverse Reactions (Section 6.2)**:
  - **Summary**: There have been several postmarketing reports of angioedema associated with the use of TRACLEER. The onset of the reported cases occurred within a range of 8 hours to 21 days after starting therapy. Some patients were treated with an antihistamine and their signs of angioedema resolved without discontinuing TRACLEER.
  - **Association**: The drug itself is associated with angioedema.
 

 4. **Postmarketing Experience (Section 6.2)**:
  - **Summary**: The following additional adverse reactions have been reported during the postapproval use of TRACLEER: Hypersensitivity, DRESS, and anaphylaxis.
  - **Association**: The drug itself is associated with these dermatological reactions.
 

 5. **Patient Counseling Information (Section 17)**:
  - **Summary**: Instruct patients that the risks associated with TRACLEER include hypersensitivity reactions such as rash.
  - **Association**: The drug itself is associated with hypersensitivity reactions, including rash.
 

 In summary, TRACLEER (bosentan) is associated with several dermatological and cutaneous risks, including hypersensitivity reactions, DRESS, anaphylaxis, rash, and angioedema. These reactions have been observed both in clinical settings and postmarketing reports.",Most,Yes,1,1,,
INSULIN LISPRO-AABC,"Sure, here is a summary of the parts of the drug label that discuss dermatological and cutaneous risks and reactions associated with LYUMJEV:
 

 1. **Lipodystrophy and Localized Cutaneous Amyloidosis**:
  - **Risk**: LYUMJEV can cause lipodystrophy (pits in the skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.
  - **Recommendation**: Rotate injection sites within the same region to reduce the risk of these conditions. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis.
 

 2. **Injection/Infusion Site Reactions**:
  - **Risk**: LYUMJEV can cause injection or infusion site reactions, including rash, redness, inflammation, pain, bruising, or itching at the site of injection or infusion.
  - **Specific Ingredients**: LYUMJEV contains treprostinil sodium and sodium citrate dihydrate, which have been associated with infusion and injection site reactions in other non-insulin products.
 

 3. **Clinical Trials Experience**:
  - **Adult Patients with Type 1 Diabetes**: In clinical trials, infusion site reactions occurred in 19.1% of patients, and infusion site pain occurred in 15.8% of patients using LYUMJEV.
  - **Pediatric Patients with Type 1 Diabetes**: Injection site-related reactions occurred in 6.2% of pediatric patients treated with LYUMJEV.
 

 4. **Postmarketing Experience**:
  - **Risk**: Localized cutaneous amyloidosis at the injection site has occurred with insulin use, including LYUMJEV. Hyperglycemia has been reported with repeated insulin injections into areas of localized cutaneous amyloidosis; hypoglycemia has been reported with a sudden change to an unaffected injection site.
 

 5. **Patient Counseling Information**:
  - **Advice**: Patients should be informed about the risk of lipodystrophy and localized cutaneous amyloidosis and advised to rotate injection sites within the chosen area to reduce these risks. They should also be instructed not to inject into areas where the skin has pits, is thickened, or has lumps.
 

 In summary, LYUMJEV itself is associated with or causes dermatological risks such as lipodystrophy, localized cutaneous amyloidosis, and injection/infusion site reactions. The drug label provides recommendations to mitigate these risks, such as rotating injection sites and avoiding injection into affected areas.",Most,Yes,1,1,,
ROSUVASTATIN CALCIUM; ROSUVASTATIN CALCIUN,"Here is a summary of the parts of the drug label that discuss dermatological and cutaneous risks and reactions for rosuvastatin calcium:
 

 1. **Hypersensitivity Reactions**:
  - **Sentence**: ""Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin.""
  - **Summary**: The drug itself has been associated with hypersensitivity reactions, including rash, pruritus (itching), urticaria (hives), and angioedema (swelling).
 

 2. **Adverse Reactions in Clinical Studies**:
  - **Sentence**: ""Other adverse reactions reported in clinical studies were abdominal pain, dizziness, hypersensitivity (including rash, pruritus, urticaria, and angioedema) and pancreatitis.""
  - **Summary**: The drug itself was associated with hypersensitivity reactions, including rash, pruritus, urticaria, and angioedema, as reported in clinical studies.
 

 3. **Postmarketing Experience**:
  - **Sentence**: ""The following adverse reactions have been identified during postapproval use of rosuvastatin: arthralgia, fatal and non-fatal hepatic failure, hepatitis, jaundice, thrombocytopenia, depression, sleep disorders (including insomnia and nightmares), peripheral neuropathy, interstitial lung disease, and gynecomastia.""
  - **Summary**: The drug itself was associated with various adverse reactions, but this sentence does not specifically mention dermatological reactions.
  - **Sentence**: ""There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use.""
  - **Summary**: This sentence does not mention dermatological reactions.
  - **Sentence**: ""There have been rare reports of immune-mediated necrotizing myopathy associated with statin use.""
  - **Summary**: This sentence does not mention dermatological reactions.
 

 4. **Risk of Allergic Reactions due to Tartrazine**:
  - **Sentence**: ""Rosuvastatin calcium tablets, 5 mg contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons.""
  - **Summary**: The drug itself contains tartrazine, which may cause allergic-type reactions, but this sentence does not specifically mention dermatological reactions.
 

 In summary, the drug label indicates that rosuvastatin calcium is associated with dermatological risks and reactions, including rash, pruritus, urticaria, and angioedema, as part of hypersensitivity reactions. These reactions were reported both in clinical studies and postmarketing experience.",Less,Yes,1,1,,"**this should be the same label as #32, the other rosuvastatin"
FERRIC PYROPHOSPHATE; FERRIC PYROPHOSPHATE CITRATE,"The drug label for Triferic mentions dermatological and cutaneous risks and reactions in the following sections:
 

 1. **Warnings and Precautions (5.1 Hypersensitivity Reactions)**
  - **Summary**: Serious hypersensitivity reactions, including anaphylactic-type reactions, have been reported in patients receiving parenteral iron products. These reactions can include symptoms such as rash and itching.
  - **Association**: The drug itself (Triferic) is associated with these hypersensitivity reactions, which can manifest as dermatological symptoms like rash and itching.
 

 2. **Adverse Reactions (6.1 Clinical Trials Experience)**
  - **Summary**: Hypersensitivity reactions were reported in 1 (0.3%) of 292 patients receiving Triferic in two randomized clinical trials.
  - **Association**: The drug itself (Triferic) caused hypersensitivity reactions, which may include dermatological symptoms.
 

 3. **Patient Counseling Information (17)**
  - **Summary**: Patients should be advised to report any signs and symptoms of hypersensitivity that may develop during and after the dialysis session, such as rash and itching.
  - **Association**: The drug itself (Triferic) is associated with hypersensitivity reactions, which can include dermatological symptoms like rash and itching.
 

 In summary, Triferic is associated with dermatological risks primarily through hypersensitivity reactions, which can manifest as rash and itching. These reactions have been observed in clinical trials and patients are advised to report such symptoms.",Less,Yes,1,1,,
ATRACURIUM BESYLATE,"Here is a summary of the parts of the drug label that discuss dermatological and cutaneous risks and reactions for Atracurium Besylate Injection USP:
 

 1. **Adverse Reactions (Observed in Controlled Clinical Studies)**
  - **Skin Flush**: The drug was associated with skin flush in 5.0% of patients overall, with higher incidences at higher doses (1.0% at 0.00-0.30 mg/kg, 8.7% at 0.31-0.50 mg/kg, and 29.2% at ≥0.60 mg/kg).
  - **Erythema**: The drug was associated with erythema in 0.6% of patients overall, with similar incidences across different doses (0.6% at 0.00-0.30 mg/kg, 0.5% at 0.31-0.50 mg/kg, and 0% at ≥0.60 mg/kg).
  - **Itching**: The drug was associated with itching in 0.2% of patients overall, with incidences of 0.4% at 0.00-0.30 mg/kg and 0% at higher doses.
  - **Hives**: The drug was associated with hives in 0.1% of patients overall, with incidences of 0.2% at 0.00-0.30 mg/kg and 0% at higher doses.
 

 2. **Adverse Reactions (Observed in Clinical Practice)**
  - **Rash**: The drug was associated with rash, but the incidence rate is not specified.
  - **Urticaria**: The drug was associated with urticaria, but the incidence rate is not specified.
  - **Reaction at Injection Site**: The drug was associated with reactions at the injection site, but the incidence rate is not specified.
 

 3. **Warnings**
  - **Anaphylaxis**: The drug has been associated with severe anaphylactic reactions, which can include dermatological symptoms such as rash and urticaria.
 

 In summary, Atracurium Besylate Injection USP has been associated with several dermatological and cutaneous reactions, including skin flush, erythema, itching, hives, rash, urticaria, and reactions at the injection site. These reactions were observed in both controlled clinical studies and clinical practice. Additionally, severe anaphylactic reactions, which can include dermatological symptoms, have been reported.",Less,Yes,1,1,,
BENAZEPRIL HYDROCHLORIDE,"### Summary of Dermatological and Cutaneous Risks and Reactions for Lotensin (Benazepril Hydrochloride)
 

 1. **Adverse Reactions (Section 6)**
  - **Dermatologic Reactions:**
  - **Stevens-Johnson Syndrome:** The drug was associated with this severe skin reaction.
  - **Pemphigus:** The drug was associated with this autoimmune blistering disorder.
  - **Apparent Hypersensitivity Reactions:** The drug was associated with dermatitis, pruritus (itching), or rash.
  - **Photosensitivity:** The drug was associated with increased sensitivity to sunlight.
  - **Flushing:** The drug was associated with this reaction, which involves redness of the skin.
 

 2. **Warnings and Precautions (Section 5)**
  - **Angioedema and Anaphylactoid Reactions (Section 5.2):**
  - **Angioedema:** The drug can cause angioedema, which may involve swelling of the face, extremities, lips, tongue, glottis, and/or larynx. This reaction can be severe and potentially fatal.
 

 3. **Patient Counseling Information (Section 17)**
  - **Angioedema:** Patients are advised to report any signs or symptoms suggesting angioedema (such as swelling of the face, eyes, lips, or tongue, or difficulty in breathing) immediately and to discontinue the drug until consulting with the prescribing physician. This indicates that the drug can cause angioedema.
 

 ### Summary
 - **Stevens-Johnson Syndrome, Pemphigus, Hypersensitivity Reactions (dermatitis, pruritus, rash), Photosensitivity, and Flushing:** These dermatological reactions are associated with the use of Lotensin.
 - **Angioedema:** This severe cutaneous reaction is caused by Lotensin and can be life-threatening, requiring immediate medical attention.",Most,Yes,1,1,,
FEBUXOSTAT,"Here is a summary of the parts of the drug label that discuss dermatological and cutaneous risks and reactions for ULORIC (febuxostat):
 

 1. **Warnings and Precautions (5.4) - Serious Skin Reactions:**
  - **Sentence:** ""Serious skin and hypersensitivity reactions, including Stevens-Johnson Syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) and toxic epidermal necrolysis (TEN) have been reported in patients taking ULORIC.""
  - **Summary:** The drug ULORIC is associated with serious skin and hypersensitivity reactions, including Stevens-Johnson Syndrome, DRESS, and TEN.
  - **Sentence:** ""Discontinue ULORIC if serious skin reactions are suspected.""
  - **Summary:** The drug ULORIC should be discontinued if serious skin reactions are suspected.
  - **Sentence:** ""Many of these patients had reported previous similar skin reactions to allopurinol.""
  - **Summary:** The drug ULORIC is associated with serious skin reactions, especially in patients who had similar reactions to allopurinol.
  - **Sentence:** ""ULORIC should be used with close monitoring in these patients.""
  - **Summary:** The drug ULORIC should be used with close monitoring in patients with a history of similar skin reactions to allopurinol.
 

 2. **Adverse Reactions (6.1) - Clinical Trials Experience:**
  - **Sentence:** ""Adverse reactions in ≥ 1% of patients treated with ULORIC are liver function abnormalities, nausea, arthralgia, and rash.""
  - **Summary:** The drug ULORIC is associated with rash in ≥ 1% of patients.
  - **Sentence:** ""In addition to the adverse reactions presented in Table 1, dizziness was reported in more than 1% of patients treated with ULORIC although not at a rate more than 0.5% greater than placebo.""
  - **Summary:** The drug ULORIC is associated with dizziness in more than 1% of patients.
  - **Sentence:** ""In the CARES study, liver function abnormalities and diarrhea were reported in more than 1% of patients treated with ULORIC, although not at a rate more than 0.5% greater than allopurinol.""
  - **Summary:** The drug ULORIC is associated with liver function abnormalities and diarrhea in more than 1% of patients.
 

 3. **Adverse Reactions (6.1) - Less Common Adverse Reactions:**
  - **Sentence:** ""In clinical studies the following adverse reactions occurred in less than 1% of patients and in more than one subject treated with doses ranging from 40 mg to 240 mg of ULORIC.""
  - **Summary:** The drug ULORIC is associated with less common adverse reactions occurring in less than 1% of patients.
  - **Sentence:** ""Skin and Subcutaneous Tissue Disorders: alopecia, angioedema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis, peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.""
  - **Summary:** The drug ULORIC is associated with various skin and subcutaneous tissue disorders, including alopecia, angioedema, dermatitis, and others.
 

 4. **Adverse Reactions (6.2) - Postmarketing Experience:**
  - **Sentence:** ""The following adverse reactions have been identified during post approval use of ULORIC.""
  - **Summary:** The drug ULORIC is associated with adverse reactions identified during post-approval use.
  - **Sentence:** ""Skin and Subcutaneous Tissue Disorders: generalized rash, Stevens-Johnson Syndrome, hypersensitivity skin reactions, erythema multiforme, drug reaction with eosinophilia and systemic symptoms, toxic epidermal necrolysis.""
  - **Summary:** The drug ULORIC is associated with various serious skin and subcutaneous tissue disorders, including generalized rash, Stevens-Johnson Syndrome, and others.
 

 5. **Patient Counseling Information (17) - Serious Skin Reactions:**
  - **Sentence:** ""Inform patients that serious skin and hypersensitivity reactions have occurred in patients treated with ULORIC.""
  - **Summary:** The drug ULORIC is associated with serious skin and hypersensitivity reactions.
  - **Sentence:** ""Instruct patients to discontinue ULORIC if they develop symptoms of these reactions.""
  - **Summary:** The drug ULORIC should be discontinued if patients develop symptoms of serious skin reactions.
 

 6. **Medication Guide - Severe Skin and Allergic Reactions:**
  - **Sentence:** ""Serious skin and allergic reactions that may affect different parts of the body such as your liver, kidneys, heart or lungs, can happen in people who take ULORIC.""
  - **Summary:** The drug ULORIC is associated with serious skin and allergic reactions that may affect various parts of the body.
  - **Sentence:** ""Call your doctor right away or get emergency medical help if you have any of the following symptoms: rash, red and painful skin, severe skin blisters, peeling skin, sores around the lips, eyes or mouth, swollen face, lips, mouth, tongue or throat, flu-like symptoms.""
  - **Summary:** The drug ULORIC is associated with symptoms of serious skin and allergic reactions, including rash, red and painful skin, and others.
 

 In summary, ULORIC (febuxostat) is associated with various dermatological and cutaneous risks and reactions, including serious conditions such as Stevens-Johnson Syndrome, DRESS, and TEN, as well as more common reactions like rash and dermatitis. Patients should be closely monitored for these reactions, and the drug should be discontinued if serious skin reactions are suspected.",Most,Yes,1,1,,
SODIUM IOTHALAMATE I-125 INJECTION,"The drug label for Glofil-125 does not specifically mention any dermatological or cutaneous risks or reactions. Here is a summary of the relevant sections that might typically discuss such risks, confirming that no dermatological issues are associated with the drug:
 

 1. **Warnings**: The label states ""None known,"" indicating that no known warnings, including dermatological risks, are associated with the drug.
 

 2. **Precautions**: The general precautions focus on minimizing radiation exposure and ensuring proper handling by qualified professionals. There is no mention of dermatological risks or reactions.
 

 3. **Adverse Reactions**: The label states ""None Reported,"" indicating that no adverse reactions, including dermatological reactions, have been reported for this drug.
 

 4. **Pregnancy Category C**: This section discusses the lack of animal reproduction studies and the unknown effects on fetal harm or reproductive capacity but does not mention any dermatological risks.
 

 5. **Nursing Mothers**: The label mentions that it is not known whether Glofil-125 is excreted in human milk and advises substituting formula feedings for breast feedings. There is no mention of dermatological risks.
 

 6. **Pediatric Use**: The safety and effectiveness in children have not been established, but no specific dermatological risks are mentioned.
 

 In summary, the drug label for Glofil-125 does not associate the drug with any dermatological or cutaneous risks or reactions.",No,No,1,1,,
VONOPRAZAN FUMARATE,"### Summary of Dermatological and Cutaneous Risks and Reactions for VOQUEZNA (vonoprazan)
 

 1. **Severe Cutaneous Adverse Reactions (Section 5.5)**
  - **Summary:** Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with VOQUEZNA.
  - **Association:** The drug itself was associated with these severe cutaneous adverse reactions.
 

 2. **Warnings and Precautions (Section 5.5)**
  - **Summary:** Discontinue VOQUEZNA at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation.
  - **Association:** The drug itself was associated with the need to discontinue use at the first signs of severe cutaneous adverse reactions.
 

 3. **Adverse Reactions (Section 6.1)**
  - **Summary:** Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with VOQUEZNA.
  - **Association:** The drug itself was associated with these severe cutaneous adverse reactions.
 

 4. **Postmarketing Experience (Section 6.2)**
  - **Summary:** The following additional adverse reactions have been identified during post-approval use of vonoprazan outside of the United States: drug eruption, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
  - **Association:** The drug itself was associated with these dermatological reactions during post-approval use.
 

 5. **Patient Counseling Information (Section 17)**
  - **Summary:** Advise patients to discontinue VOQUEZNA and report to their healthcare provider at the first appearance of a severe cutaneous adverse reaction or other sign of hypersensitivity.
  - **Association:** The drug itself was associated with the need for patients to discontinue use at the first signs of severe cutaneous adverse reactions.
 

 6. **Patient Information (Section 17)**
  - **Summary:** VOQUEZNA can cause rare but severe skin reactions that may affect any part of your body. These serious skin reactions may need to be treated in a hospital and may be life-threatening.
  - **Association:** The drug itself was associated with causing rare but severe skin reactions.
 

 7. **Patient Information (Section 17)**
  - **Summary:** Skin rash which may have blistering, peeling, or bleeding on any part of your skin (including your lips, eyes, mouth, nose, genital, hands, or feet). You may also have fever, chills, body aches, shortness of breath, or enlarged lymph nodes.
  - **Association:** The drug itself was associated with causing skin rash with blistering, peeling, or bleeding.
 

 8. **Patient Information (Section 17)**
  - **Summary:** If you have any of these symptoms, stop taking VOQUEZNA and call your healthcare provider right away. These symptoms may be the first sign of a severe skin reaction.
  - **Association:** The drug itself was associated with the need to stop taking it if severe skin reaction symptoms appear.
 

 ### Conclusion
 VOQUEZNA (vonoprazan) is associated with several severe dermatological and cutaneous risks, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug eruption, and erythema multiforme. Patients are advised to discontinue use and seek medical attention at the first signs of these severe skin reactions.",Most,Yes,1,1,,
BETAINE ANHYDROUS,"The drug label for Betaine Anhydrous for Oral Solution mentions dermatological and cutaneous risks and reactions in the following sections:
 

 1. **Adverse Reactions (6.2 Post-marketing Experience)**:
  - **Hair loss**: This reaction has been identified during post-approval use of Betaine Anhydrous for Oral Solution. The label does not explicitly state that the drug itself caused hair loss, but it is listed as an adverse reaction reported by patients.
  - **Hives**: This reaction has also been identified during post-approval use. Similar to hair loss, the label does not explicitly state that the drug caused hives, but it is listed as an adverse reaction reported by patients.
  - **Skin odor abnormalities**: This reaction has been identified during post-approval use. The label does not explicitly state that the drug caused skin odor abnormalities, but it is listed as an adverse reaction reported by patients.
 

 In summary, the drug label mentions hair loss, hives, and skin odor abnormalities as dermatological reactions reported during post-marketing experience. While the label does not explicitly state that Betaine Anhydrous for Oral Solution caused these reactions, they are associated with its use based on patient reports.",Less,Yes,1,1,,
CAPIVASERTIB,"### Summary of Dermatological and Cutaneous Risks and Reactions for TRUQAP (Capivasertib)
 

 1. **Warnings and Precautions (Section 5.3)**
  - **Cutaneous Adverse Reactions**: TRUQAP is associated with cutaneous adverse reactions, which can be severe, including erythema multiforme (EM), palmar-plantar erythrodysesthesia, and drug reaction with eosinophilia and systemic symptoms (DRESS).
  - **Incidence**: Cutaneous adverse reactions occurred in 58% of patients treated with TRUQAP.
  - **Severity**: Grade 3 or 4 cutaneous adverse reactions occurred in 17% of patients receiving TRUQAP.
  - **Specific Conditions**: EM occurred in 1.7% of patients and DRESS occurred in 0.3% of patients treated with TRUQAP.
  - **Dose Adjustments**: Dose reduction was required in 7% of patients, and 7% of patients permanently discontinued TRUQAP due to cutaneous adverse reactions.
  - **Onset**: The median time to onset of cutaneous adverse reactions was 13 days (range 1 to 575 days).
  - **Treatment**: Among the 204 patients with cutaneous adverse reactions, 44% required corticosteroid treatment. Of these, 37% were treated with topical corticosteroids and 19% with systemic corticosteroids.
  - **Improvement**: In patients with Grade ≥ 2 cutaneous adverse reactions, the median time to improvement from the first event was 12 days (range 2 to 544).
  - **Monitoring**: Patients should be monitored for signs and symptoms of cutaneous adverse reactions. Early consultation with a dermatologist is recommended. TRUQAP should be withheld, the dose reduced, or permanently discontinued based on severity.
 

 2. **Adverse Reactions (Section 6.1)**
  - **Clinical Trials Experience**: In the CAPItello-291 trial, cutaneous adverse reactions were reported in 58% of patients treated with TRUQAP.
  - **Serious Adverse Reactions**: Serious cutaneous adverse reactions occurred in 3.9% of patients receiving TRUQAP with fulvestrant.
  - **Permanent Discontinuation**: Cutaneous adverse reactions were the most common reason for permanent discontinuation of TRUQAP, occurring in 6% of patients.
  - **Dosage Interruptions**: Cutaneous adverse reactions led to dosage interruptions in 14% of patients.
  - **Dose Reductions**: Cutaneous adverse reactions led to dose reductions in 8% of patients.
 

 3. **Patient Counseling Information (Section 17)**
  - **Cutaneous Adverse Reactions**: Patients should be advised that TRUQAP can cause cutaneous adverse reactions and to contact their healthcare provider immediately to report new or worsening rash, erythematous, and exfoliative skin reactions.
 

 4. **Patient Information Leaflet**
  - **Skin Reactions**: Patients are advised to tell their healthcare provider or get medical help right away if they get a rash or if the rash keeps getting worse, reddening of the skin, fever, blistering of the lips, eyes or mouth, blisters on the skin, skin peeling, or dry skin.
 

 ### Summary
 TRUQAP (capivasertib) is associated with a significant risk of dermatological and cutaneous adverse reactions, including severe conditions such as erythema multiforme (EM) and drug reaction with eosinophilia and systemic symptoms (DRESS). These reactions occurred in a substantial proportion of patients (58%) and led to dose reductions, interruptions, and permanent discontinuations in some cases. Patients should be closely monitored for these reactions, and early consultation with a dermatologist is recommended. Patients are also advised to report any new or worsening skin reactions to their healthcare provider immediately.",Most,Yes,1,1,,
ISOSORBIDE MONONITRATE,"The drug label for Isosorbide Mononitrate Extended-Release Tablets, USP mentions dermatological and cutaneous risks and reactions in the following sections:
 

 1. **Adverse Reactions:**
  - **Skin and Appendages Disorders:**
  - **Acne:** Reported by ≤5% of exposed patients. The label does not specify if the drug itself caused acne, but it is listed as an adverse event.
  - **Hair texture abnormal:** Reported by ≤5% of exposed patients. The label does not specify if the drug itself caused this condition, but it is listed as an adverse event.
  - **Increased sweating:** Reported by ≤5% of exposed patients. The label does not specify if the drug itself caused increased sweating, but it is listed as an adverse event.
  - **Pruritus (itching):** Reported by ≤5% of exposed patients. The label does not specify if the drug itself caused pruritus, but it is listed as an adverse event.
  - **Rash:** Reported by ≤5% of exposed patients. The label does not specify if the drug itself caused the rash, but it is listed as an adverse event.
  - **Skin nodule:** Reported by ≤5% of exposed patients. The label does not specify if the drug itself caused skin nodules, but it is listed as an adverse event.
 

 In summary, the drug label lists several dermatological reactions such as acne, abnormal hair texture, increased sweating, pruritus, rash, and skin nodules. However, it does not explicitly state that the drug itself caused these conditions, only that they were reported by a small percentage of patients exposed to the drug.",Less,Yes,1,1,,
FLUDEOXYGLUCOSE F-18 INJECTION,"The drug label for Fludeoxyglucose F-18 Injection does not specifically discuss any dermatological or cutaneous risks or reactions. Here is a summary of the relevant sections:
 

 1. **Warnings**: The label states ""None known,"" indicating that there are no known warnings associated with dermatological risks caused by the drug.
 

 2. **Contraindications**: The label states ""None known,"" indicating that there are no known contraindications related to dermatological conditions caused by the drug.
 

 3. **Precautions**: The label does not mention any dermatological precautions, implying that the drug is not associated with any specific dermatological risks.
 

 4. **Adverse Reactions**: The label does not list any dermatological reactions among the adverse reactions reported. It mentions that in a database of 374 patients, adverse drug reactions requiring medical intervention were not reported, and in a subset of 42 patients, there were no dermatological reactions reported.
 

 5. **Overdose**: The label does not discuss any dermatological risks or reactions in the context of an overdose of the drug.
 

 In summary, the drug label for Fludeoxyglucose F-18 Injection does not associate the drug with any dermatological or cutaneous risks or reactions.",No,No,1,1,,"**i would fact check this, whether it is really no side effects or just not documented yet "
FREMANEZUMAB-VFRM,"### Summary of Dermatological and Cutaneous Risks and Reactions for AJOVY
 

 1. **Hypersensitivity Reactions (Section 5.1)**
  - **Summary**: Hypersensitivity reactions, including rash, pruritus (itching), drug hypersensitivity, and urticaria (hives), were reported with AJOVY in clinical trials.
  - **Association**: The drug itself was associated with these dermatological reactions.
 

 2. **Clinical Trials Experience (Section 6.1)**
  - **Summary**: Injection site reactions were the most common adverse reactions in clinical trials for AJOVY, occurring in at least 5% of patients and more frequently than in the placebo group.
  - **Association**: The drug itself was associated with these dermatological reactions.
 

 3. **Postmarketing Experience (Section 6.3)**
  - **Summary**: Anaphylactic reactions and angioedema, which can include severe skin reactions, have been identified during postapproval use of AJOVY.
  - **Association**: The drug itself was associated with these dermatological risks.
 

 4. **Patient Information (Section 17)**
  - **Summary**: Patients are advised to be aware of signs and symptoms of hypersensitivity reactions, including itching, rash, and hives, which can occur up to one month after administration of AJOVY.
  - **Association**: The drug itself was associated with these dermatological reactions.
 

 5. **Possible Side Effects (Patient Information Section)**
  - **Summary**: The most common side effects of AJOVY include injection site reactions.
  - **Association**: The drug itself was associated with these dermatological reactions.
 

 6. **Instructions for Use (Prefilled Autoinjector and Prefilled Syringe)**
  - **Summary**: Patients are instructed not to inject AJOVY into areas that are tender, red, bruised, callused, tattooed, hard, or that have scars or stretch marks.
  - **Association**: This instruction is to avoid exacerbating existing dermatological conditions, but it does not imply that the drug itself causes these conditions.
 

 ### Conclusion
 AJOVY is associated with several dermatological and cutaneous risks, primarily hypersensitivity reactions such as rash, pruritus, urticaria, and injection site reactions. These reactions were observed both in clinical trials and postmarketing experiences. Patients are advised to monitor for these reactions and avoid injecting into compromised skin areas.",Most,Yes,1,1,,
BETAXOLOL HYDROCHLORIDE,"The drug label for BETOPTIC S (betaxolol hydrochloride ophthalmic suspension) mentions several dermatological and cutaneous risks and reactions. Here is a summary of those parts:
 

 1. **Section 6: Adverse Reactions**
  - **Other Reactions**: ""Hives, toxic epidermal necrolysis, hair loss and glossitis. Perversions of taste and smell have been reported.""
  - **Summary**: The drug itself was associated with hives, toxic epidermal necrolysis, hair loss, and glossitis. Additionally, perversions of taste and smell were reported.
 

 2. **Section 7: Drug Interactions**
  - **No specific dermatological risks or reactions mentioned in this section.**
 

 3. **Section 8: Use in Specific Populations**
  - **No specific dermatological risks or reactions mentioned in this section.**
 

 4. **Section 11: Description**
  - **No specific dermatological risks or reactions mentioned in this section.**
 

 5. **Section 12: Clinical Pharmacology**
  - **No specific dermatological risks or reactions mentioned in this section.**
 

 6. **Section 13: Nonclinical Toxicology**
  - **No specific dermatological risks or reactions mentioned in this section.**
 

 7. **Section 14: Clinical Studies**
  - **No specific dermatological risks or reactions mentioned in this section.**
 

 8. **Section 16: How Supplied/Storage and Handling**
  - **No specific dermatological risks or reactions mentioned in this section.**
 

 9. **Section 17: Patient Counseling Information**
  - **Avoiding Contamination of the Product**: ""Instruct patients to avoid allowing the tip of the dispensing container to contact the eye(s) or surrounding structures. Also instruct patients that ocular solutions, if handled improperly, could become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye(s) and subsequent loss of vision may result from using contaminated solutions.""
  - **Summary**: This section does not directly associate the drug itself with dermatological risks but advises on avoiding contamination to prevent infections, which could indirectly lead to dermatological issues.
 

 In summary, the drug itself was associated with hives, toxic epidermal necrolysis, hair loss, and glossitis. There are no other specific dermatological risks or reactions mentioned in the other sections of the drug label.",Less,Yes,1,1,,
ANASTROZOLE,"Here is a summary of the parts of the drug label that discuss dermatological and cutaneous risks and reactions associated with ARIMIDEX (anastrozole):
 

 1. **Section 4 - Contraindications:**
  - **Hypersensitivity:** ARIMIDEX is contraindicated in patients who have shown hypersensitivity reactions to the drug or its excipients, including skin reactions such as lesions, ulcers, or blisters. **(The drug itself is associated with these dermatological risks.)**
 

 2. **Section 5 - Warnings and Precautions:**
  - **Serious Adverse Reactions:** Serious adverse reactions with ARIMIDEX occurring in less than 1 in 10,000 patients include skin reactions such as lesions, ulcers, or blisters. **(The drug itself is associated with these dermatological risks.)**
 

 3. **Section 6 - Adverse Reactions:**
  - **Common Adverse Reactions:** Common adverse reactions (occurring with an incidence of ≥10%) in women taking ARIMIDEX included rash. **(The drug itself is associated with this dermatological reaction.)**
  - **Post-Marketing Experience:** Rash, including cases of mucocutaneous disorders such as erythema multiforme and Stevens-Johnson syndrome, has been reported in post-approval use of ARIMIDEX. **(The drug itself is associated with these dermatological risks.)**
 

 4. **Section 17 - Patient Counseling Information:**
  - **Skin Reactions:** Patients should be informed that ARIMIDEX can cause skin reactions, including lesions, ulcers, or blisters, and they should stop taking the drug and call their healthcare provider right away if these occur. **(The drug itself is associated with these dermatological risks.)**
 

 5. **Patient Information Leaflet:**
  - **Skin Reactions:** Patients are advised to stop taking ARIMIDEX and call their healthcare provider right away if they get any skin lesions, ulcers, or blisters. **(The drug itself is associated with these dermatological risks.)**
 

 In summary, ARIMIDEX is associated with several dermatological risks and reactions, including skin lesions, ulcers, blisters, rash, erythema multiforme, and Stevens-Johnson syndrome. These risks are directly linked to the drug itself.",Most,Yes,1,1,,